The University of Bradford Institutional Repository

<http://bradscholars.brad.ac.uk>

This work is made available online in accordance with publisher policies. Please refer to the repository record for this item and our Policy Document available from the repository home page for further information.

To see the final version of this work please visit the publisher's website. Available access to the published online version may require a subscription.

Link to original published version: <http://dx.doi.org/10.1021/jm401121k>

Citation: Pletsas D, Garelnabi EAE, Li L, Phillips RM and Wheelhouse RT (2013) Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA methyltransferase, DNA Mismatch Repair and p53. *Journal of Medicinal Chemistry*. 56(17): 7120-7132.

Copyright statement: © 2013 American Chemical Society. Full-text reproduced in accordance with the publisher's self-archiving policy.

Synthesis and Quantitative Structure–Activity Relationship of Imidazotetrazine Prodrugs with Activity Independent of O6-Methylguanine-DNA- methyltransferase, DNA Mismatch Repair and p53.

Dimitrios Pletsas,[†] Elrashied A.E. Garelnabi,^{†§} Li Li,[‡] Roger M. Phillips,[‡] Richard T. Wheelhouse^{†}*

[†]School of Pharmacy and [‡]Institute of Cancer Therapeutics,

University of Bradford, BRADFORD, BD7 1DP, UK.

This document is the unedited Author's version of a Submitted Work that was subsequently accepted for publication in Journal of Medicinal Chemistry copyright © American Chemical Society after peer review. To access the final edited and published work see <http://pubs.acs.org/articlesonrequest/AOR-FqkUjA929M3ezTZ2TnvX>

Abstract

The antitumor prodrug Temozolomide is compromised by its dependence for activity on DNA mismatch repair (MMR) and the repair of the chemosensitive DNA lesion, *O*6-methylguanine (*O*6-MeG), by *O*6-methylguanine-DNA-methyltransferase (EC 2.1.1.63, MGMT). Tumor response is also dependent on wild-type p53. Novel 3-(2-anilinoethyl)-substituted imidazotetrazines are reported that have activity independent of MGMT, MMR and p53. This is achieved through a switch of mechanism so that bioactivity derives from imidazotetrazine-generated arylaziridinium ions that principally modify guanine-*N*7 sites on DNA. Mono- and bi-functional analogs are reported and a quantitative structure-activity relationship (QSAR) study identified the *p*-tolyl-substituted bi-functional congener as optimized for potency, MGMT-independence and MMR-independence. NCI60 data show the tumor cell response is distinct from other imidazotetrazines and DNA-guanine-*N*7 active agents such as nitrogen mustards and cisplatin. The new imidazotetrazine compounds are promising agents for further development and their improved *in vitro* activity validates the principles on which they were designed.

Introduction

The imidazotetrazine prodrug temozolomide **1** (TMZ), a DNA methylating agent, in combination with radiotherapy, is now first line treatment for glioblastoma multiforme (GBM) in North America and Europe. However, intrinsic and acquired resistance significantly limits the ultimate efficacy of therapy. In particular, tumor re-growth up to two years following TMZ treatment is aggressive and resistant to further TMZ therapy.¹⁻³ This paper reports new compounds of the TMZ class that have activity independent of the two principal constraints on the ability of a tumor to respond to TMZ therapy: MGMT activity which directly repairs TMZ *O*6-methylation of DNA, and MMR which enables the tumor response to TMZ therapy.²

Scheme 1. The mechanism of action of temozolomide **1**.

At neutral pH, TMZ is relatively unstable ($t_{1/2} = 1.24$ h, pH 7.4)⁴ and undergoes hydrolytic ring-cleavage to the open chain triazene 5-(3-methyltriazene-1-yl)-imidazole-4-carboxamide (MTIC, $t_{1/2} = 8$ min, pH 7.4),⁵ which then fragments to the highly reactive electrophile, methyldiazonium ($t_{1/2} = 0.39$ sec, pH 7.4).⁶⁻⁸ Methyldiazonium reacts with nucleophilic groups on DNA, resulting in DNA methylation, Scheme 1. Approximately 70% of the methyl groups transferred to DNA appear at *N*7-guanine, 10 % at *N*3-adenine, and 5 % at *O*6-guanine sites. The *N*-methylation products are readily repaired by the base-excision repair pathways so are not major contributors to chemosensitivity.⁹ In contrast, *O*6-MeG lesions are reversed by direct removal by the MGMT protein. The MGMT gene is silenced by promoter methylation in approximately 35% of GBM.¹ In these tumors, persistent *O*6-MeG lesions form wobble base-pairs with thymidine during replication; *O*6-MeG=T pairings result in futile cycles of mismatch repair, leading to stalled replication forks, DNA double-strand breaks and ultimately cell death.¹ Low levels of MMR expression (or mutations leading to non-functional MMR) lead to a tolerant phenotype that cannot respond to TMZ. Consistent with these mechanisms of *O*6-MeG processing and repair, high-level expression of the MGMT protein is a major mechanism of inherent TMZ resistance in primary tumors. Down regulation or mutations of the MMR pathway or up-

regulation of MGMT expression are important causes of acquired TMZ resistance in GBM.² Herein we report the synthesis, pre-clinical activity *in vitro* and QSAR of new imidazotetrazines that have activity independent of MMR and MGMT.

Compound Design

The imidazotetrazine bicycle is a prodrug of alkyldiazonium ions which are liberated by pH-dependent hydrolysis.⁶ Careful control of these reactive intermediates, in particular the suppression of competing side reactions, such as hydrolysis, elimination or re-arrangement,¹⁰⁻¹² is essential in the design of effective new agents.^{13,14} Furthermore, of the methyl groups transferred from TMZ to DNA, only a small fraction becomes the therapeutically-beneficial O6-MeG lesion: we sought to achieve therapeutic benefit through generation of N7-G-adducts, the major products of reaction of TMZ with DNA, thereby making more efficient use of the imidazotetrazine prodrug. We have designed novel series of mono- (**2a-i**) and bi-functional (**3a-f**) imidazotetrazines in which a 3-(2-anilinoethyl) group was substituted for the 3-methyl group of TMZ. The new compounds are efficient precursors of aziridinium ions, **4**, Scheme 2. This strategy provides for effective control of the reactivity of incipient diazonium ions using a neighboring group participation mechanism not available to TMZ. Moreover, aziridinium ions are reactive intermediates of proven clinical utility, being closely related to those generated by nitrogen mustard drugs, and are established as working through N7-guanine adducts.¹⁵ An additional feature of the drug design is the aniline *para*-substituent “X” of derivatives **2** and **3** that can be optimized to fine-tune pharmacological activity. This group affects the electron density at the aniline nitrogen by resonance or inductive effects and thereby controls the basicity and nucleophilicity of this site: i.e. the propensity either to protonate or to form an aziridinium ion. In addition, the bi-functional molecules would be expected to generate DNA cross-links, that would not be processed by MMR or

MGMT and so avert those constraints on activity; previous studies have demonstrated that polar¹⁶ and bulky¹⁷ GO6 adducts cannot be processed by MGMT.

Scheme 2. Aziridinium ion formation by imidazotetrazine **2b**.¹⁵

Synthesis

Scheme 3.

The new imidazotetrazines were prepared by variants of the established TMZ synthesis where a diazoimidazole **5** is reacted with an isocyanate **6** to yield the imidazotetrazine, Scheme 3.¹⁸ The target compounds all included an aminoethyl group in the 3-position. The requisite β -aminoisocyanate

precursors **7** are inherently unstable compounds as they bear incompatible functional groups. In the two aniline series, the anilines were sufficiently deactivated to allow isolation of the isocyanates without recourse to protecting group strategies. The formation of the relatively fragile tetrazine ring was usually planned to be the last step in the synthesis.

Scheme 4. Route to bis-imidazotetrazines **3**. *Reagents and conditions:* (i) CuCl, AcOH, Δ , 76–98%; (ii) $\text{NH}_2\text{NH}_2 \cdot x\text{H}_2\text{O}$, IPA, Δ , 64–99%; (iii) NaNO_2 , AcOH, H_2O , CH_2Cl_2 , 0 °C; (iv) PhMe, Δ , [$>95\%$]; (v) DMSO, RT, 2 d, 6–60% (over two steps)

To prepare the dimers **3a–f**, Cu(I)-catalyzed Aza-Michael conjugate addition of methyl acrylate to the requisite aniline furnished the diesters **8** in good (60–98%) yields, Scheme 4. Conversion to isocyanates **9** was achieved through the intermediate hydrazides **10** and azides **11** followed by Curtius rearrangement. For the electron rich anilines ($\text{X}=\text{CH}_3$, OMe), hydrazide formation had to be performed under very mildly acidic (0.17 M AcOH) conditions to avoid nitration of the aniline ring (**10e** $\rightarrow$ **11f** $\rightarrow$

3f). This is an attractive route as the bis-hydrazides are usually solids and easily purified while the Curtius rearrangement produces pure isocyanates directly, free from contaminating by-products.

Scheme 5 Route to mono-imidazotetrazines **2**. *Reagents and conditions:* (i) CuCl , AcOH , Δ , 58–97%; (ii) $\text{NH}_2\text{NH}_2 \cdot x\text{H}_2\text{O}$ / IPA, Δ , 44–98%; (iii) NaNO_2 , AcOH , H_2O , CH_2Cl_2 , 0°C ; (iv) PhMe , Δ , [$>95\%$]; (v) DMSO , RT, 6–51% over two steps.

The mono-imidazotetrazine analogs **2a–i** were similarly prepared from *N*-methyl anilines, Scheme 5. In one example, the secondary aniline version **2g** ($R=\text{H}$, $X=\text{Cl}$) was achieved using a BOC protection strategy that exploited the relative acid stability of the imidazotetrazine ring. Carefully controlled diazotization (**12f** $\rightarrow$ **13f** $\rightarrow$ **14f**) yielded BOC-protected isocyanatoethylaniline **15f**; tetrazine ring closure followed by final treatment with TFA gave secondary aniline **2g**. As a similar yield was obtained omitting the BOC group, the protection was shown to be redundant. The *p*-nitro derivative **2e** was accessed from hydrazide **13a** by simultaneous diazotization and nitration under more vigorous conditions (10 M HCl); the mixture of regioisomers was carried through to the final step where the *p*- NO_2 isomer, tetrazine **2e**, was isolated by flash column chromatography.

In vitro QSAR: influence of MGMT and MMR

Figure 1 . *In vitro* chemosensitivity (IC_{50} / μM) of new imidazotetrazine compounds against A2780 (MMR+) and A2780-cp70 (MMR-) cell lines in the absence (MGMT+) and presence (MGMT-) of the

MGMT inactivator PaTrin2 (10 μ M). All data are the mean of ≥ 3 determinations, error bars are the SD; t-test analysis is presented in Table S3. * $IC_{50} > 250 \mu$ M. MEL, melphalan; CP, cisplatin.

Screening of all new compounds for chemosensitizing efficacy was undertaken following a protocol by Margisson *et al* that used the MGMT and MMR-proficient ovarian carcinoma cell line A2780, and its MMR-deficient derivative A2780-cp70, Figure 1.¹⁹ To assess dependence of cytotoxicity on MGMT function, each cell line was further treated with the MGMT inactivator PaTrin2.²⁰ The data are presented graphically in Figure 1 and fully tabulated in Table S1. As expected, sensitivity to TMZ and mitozolomide (MTZ) was highly dependent on both lack of MGMT activity and presence of wild-type MMR capacity. For TMZ, the IC_{50} was $>250 \mu$ M in both A2780 and A2780-Cp70 cell lines, compared with $IC_{50} = 8.5$ and 231μ M respectively for the same cell lines co-treated with PaTrin2. In contrast, the novel imidazotetrazines were significantly more potent, with IC_{50} values in the A2780 wild-type line ranging from 22–73 μ M for the mono-functional (**2a–i**) and 1–15 μ M for the bi-functional (**3a–f**) compounds. Dependence on MMR can be examined by comparing the shaded bars with the grey bars (i.e. MMR+/MMR– with MGMT inactivated in both cases). For temozolomide the IC_{50} was >27 -fold lower in the MMR-proficient cell line. For the new bi-functional agents **3**, this ratio was reduced to 5–5.8-fold and for the mono-functional agents **2**, 2.8–10-fold. The extent of MGMT-mediated resistance can be assessed by comparing the shaded and the black bars (i.e. MGMT–/MGMT+ with MMR competent in both cases). Here, temozolomide was >30 -fold more potent when MGMT was inactivated whilst for the new agents, this ratio was 0.5–5-fold for the bi-functional and 1.1–2.9-fold for the mono-functional agents. Importantly, in the absence of MMR, all compounds showed activity greater than temozolomide irrespective of the MGMT status of the cells (white bars and grey bars) showing that

MMR-dependent toxicity and MGMT-mediated resistance are now only minor determinants of the chemosensitizing effect.

The similarity of response of examples **2d** and **2g** indicate that the *N*-methyl aniline is not essential to activity as the secondary and tertiary aniline compounds are equipotent (see Figure 1 and Table S1). Retention of the BOC group in analog **2f** significantly reduced potency, presumably by impeding the aziridine/aziridinium formation step. Nitration in the aniline ring, whether as the sole or as an additional substituent, resulted in reduced potency. This is consistent with electron withdrawal reducing nucleophilicity of the aniline and hence the propensity for aziridinium ion formation, (for examples, compare the compound pairs **3e/3f**, **2a/2e**, and **2b/2h**).

To probe the structure-activity relationship and examine MGMT and MMR dependence in more detail, the results for dimeric compounds **3a-e** were presented in Hammett plots, Figure 2. The Hammett constant σ_p is a structural parameter that measures the electron donating or withdrawing effect of the substituent “X” on the aniline ring. The plot of IC_{50} against σ_p is informative in several respects, Figure 2A. For each cell type, the graph shows a pair of lines, the dotted line being MGMT-inactivated data (i.e. PaTrin 2 present); the difference between the solid and dotted lines shows the effect of MGMT on the cellular response. For most analogs this separation is of the same order as the error bars on the data, so in effect is zero. This is a clear demonstration that these new compounds have activity independent of MGMT function and is consistent with a mechanism of action independent of guanine-*O6* alkylation (or involving a guanine-*O6* adduct that cannot be repaired by MGMT). The separation between the two pairs of lines is the MMR effect which ranges from about 2–5-fold on the IC_{50} , which is greatly reduced from the >27-fold effect measured for TMZ.

p-Methyl-substituted analog **3b** lies on a minimum in the graph so is optimally potent, with a modestly electron-donating substituent on the aniline ring, Figure 2A. The data for all analogues except **3e** (X = OMe) lie on exponential curves (see the semi-log plot, Figure 2B). The anomalous data for **3e** are likely due to enhancement of the basicity of the aniline nitrogen lone pair leading to appreciable protonation at the pH of the experiment, and thereby a reduced propensity to act as a nucleophile in the aziridinium ion-forming reaction. These data clearly demonstrate the direct effect of electron density at the aniline nitrogen in determining the *in vitro* activity of the compounds, so provide further evidence that the aziridinium ion mechanism occurs in cells.

A

B

Figure 2. (A, upper panel) Hammett plot of the IC_{50} data for the dimers **3a-e**, in each case the MGMT- data are shown in dotted lines; the substituents X are shown in circles. (B, lower panel) QSAR Semi-

log plot of log IC₅₀ vs. Hammett constant (σ -p) for the dimeric imidazotetrazines **3a–e**. Regression lines were fitted omitting the data for OMe derivative **3e**.

NCI60 Panel Data

Compounds **2d**, and **3c–e** were selected for full screening in the NCI 60 cell line panel. Mean graph data are presented in Figures S1–6 and are summarized in Table 1. These data show that the NCEs have pharmacological activity distinct from TMZ. TMZ is essentially inactive against the panel (GI₅₀ > 10⁻⁴ M for 57/60 cell lines, Figure S1). In contrast, the new agents exhibit strong patterns of discrimination over a 2–3-log range of GI₅₀ (Table 1 and Figures S2–5); this is important as it shows that the new compounds possess a degree of selectivity and are not uniformly cytotoxic against cells grown in culture. These data compare favorably with the logGI₅₀ mean and range data for established agents CHB, MEL, CP, BCNU and CCNU; this shows there is good reason to suppose that the new compounds may have an acceptable therapeutic index and be no more systemically toxic *in vivo* than these other clinically useful agents.

	Log GI ₅₀ Mean (SD)	Log GI ₅₀ range
2d	−4.69 (0.58)	2.05
3c	−5.11 (0.69)	2.81
3d	−5.07 (0.52)	1.72
3e	−4.83 (0.46)	1.80
MEL	−4.54 (0.55)	1.88
CHB	−4.21 (0.56)	1.64
CP	−5.40 (1.10)	2.38
BCNU	−4.12 (0.82)	1.86
CCNU	−4.53 (0.48)	2.22

Table 1 Summary of NCI60 statistics for compounds **2d**, **3c–e**, and established prodrugs for comparison.

Particular sensitivity is evident in the leukemia, CNS and ovarian sub-panels. In the CNS sub-panel, the pattern of activity is similar to TMZ and CP, with particular sensitivity in the glioblastoma lines SF295 and SNB75. In the ovarian sub panel, particular sensitivity is seen in the OVACR-3 and SK-OV-3 lines. Here, in contrast to the CNS activity, the new compounds show improvement over CP (see Figure S6) this is a particularly interesting result given the wide clinical use of CP against ovarian adenocarcinoma and the fact that TMZ lacks clinical activity against ovarian cancer.²¹

COMPARE analysis of mean graph data can be valuable in discerning molecular mechanisms of action. The similarity in patterns of response is assessed by the Pearson rank correlation coefficient, P: values > 0.7 are considered highly significant, values 0.6–0.7 less so.^{22, 23} Matrix COMPARE was valuable in confirming the novelty of mechanism of action of the new agents. In this method of data handling, the new compounds were compared with standard agents selected for similarities of chemical structure or predicted mechanism of action. Agents selected were other imidazotetrazines (TMZ, MTZ), nitrogen mustard cross linkers (chlorambucil CHB, melphalan MEL), nitrosoureas (1,3-Bis(2-chloroethyl)-1-nitrosourea BCNU, *N*-(2-chloroethyl)-*N'*-cyclohexyl-*N*-nitrosourea CCNU) and CP, Table 2. Correlations amongst the four new imidazotetrazine compounds examined were all strong ($0.92 \leq P \leq 0.77$) and, interestingly, there was no clear discrimination between the mono- and bi-functional agents: for monofunctional **2d**, $0.83 \leq P \leq 0.77$ and in particular $P = 0.79$ with the equivalent *p*-Cl dimer **3d**. Gratifyingly, the new compounds showed only moderate correlations ($0.52 \leq P \leq 0.38$) with the established imidazotetrazines TMZ and MTZ, so are distinct as new members of this compound class. The absence of correlation with MTZ is significant as this compound, exhibits a characteristic pattern of differential activity across the panel, unlike TMZ.

The putative DNA lesion of the bifunctional agents **3** is a five-atom crosslink, related in structure to those formed by the nitrogen mustard prodrugs; however, no drugs of this class showed strong correlations $0.59 \leq P \leq 0.29$. Notably, there was no similarity to the nitrosoureas which are also diazonium ion precursors, $0.45 \leq P \leq 0.05$. The new compounds all showed strong correlations with dacarbazine (DTIC, highest dose = 1 μ M). This observation is not easy to interpret, as this prodrug requires hepatic oxidative demethylation in order to release its active electrophile, so it is somewhat surprising that DTIC scored so highly against the new imidazotetrazines. Part of the reason for this may lie in the two relatively featureless datasets of DTIC [mean log GI₅₀(SD) = -4.30(0.28), range = 0.99, high conc. = 10⁴ M; mean log GI₅₀(SD) = -3.66(0.548), range = 2.55, high conc. = 10⁻³ M] and a shared sensitivity in the leukemia sub-panel. Simple COMPARE using DTIC GI₅₀ (high conc. = 10⁻³ M) data as seed in the Standard Agents database yields no correlations $P > 0.537$.

	2d	3c	3d	3e	TMZ	MTZ	DTIC	MEL	CHB	BCNU	CCNU	CP
2d	1	0.83	0.79	0.77	0.50	0.42	0.62	0.35	0.33	0.25	0.08	0.27
3c	0.83	1	0.92	0.92	0.52	0.35	0.72	0.4	0.33	0.32	0.06	0.32
3d	0.79	0.92	1	0.81	0.46	0.38	0.64	0.36	0.29	0.27	0.05	0.35
3e	0.77	0.92	0.81	1	0.51	0.46	0.71	0.59	0.53	0.45	0.10	0.42

Table 2. Results of Matrix COMPARE (P values) for NCEs **2d**, **3c-e** with selected standard agents.

Simple COMPARE analysis was performed with the Standard Agents and Molecular Targets databases using the GI₅₀ data as seed, Table 3. The Standard Agents data again identified similarity with DTIC, as noted above. In addition, modest correlations with 6MP and 6TG appeared for all four compounds, which is presumably linked to residual MMR-dependence,^{24,25} a property that is shared with MTZ and DTIC. With the exception of compound **3e**, correlations in the Molecular Targets database were not strong. Notable amongst the correlations of analog **3e** are the lymphocyte and

leukocyte related proteins LCP1, LRMP, RASSF5 and LAIR1 which may account for the high sensitivity of the leukemia sub-panel to these new compounds. Also intriguing are the correlations with the RAS-related proteins ARHGAP4 and RASSF5 and the moderate inverse correlation with RAB1A, a RAS superfamily GTPase.²⁶

All of the NCI cell lines are characterized for expression of MGMT and components of MMR.²⁷ Plots of protein expression vs. log GI₅₀ were prepared to probe correlation or inverse correlation between GI₅₀ and expression of MGMT, hMLH1 (the core MMR protein) or MSH6 (the MMR domain that recognizes O6-alkylG-DNA damage), see Figures S6-8. For each of the compounds **2d**, **3c-e**, the graphs showed scatters with no connection between the protein expression levels and GI₅₀: a result consistent with the independence of activity from MGMT and MMR found in the A2780 cell line screen.

Standard Agents Database				Molecular Targets Database	
P ^a	P	P	P	Strong positive correlations ^c	Strongest negative correlation
DTIC ^b	6TG	6MP		(P)	(P)
2d	0.669	0.563	0.571	U2AF1 (0.61)	RAB1A (-0.611)
3c	0.751	0.543	0.524	RCSD1 (0.686)	RAB1A (-0.636)
				HCLS1 (0.683)	
3d	0.717	0.515	0.527	WAS (0.526)	RAB1A (-0.526)
3e	0.727	0.573	0.515	HCLS1, WAS, NCKAP1L, LCPI, LRMP, ARHGAP4, RASSF5, CD53, LAIR1 (>0.7 for all)	K1AA1191 (-0.64) RAB1A (-0.5136)
TMZ					
MTZ	0.326	0.517	0.418		

^aP, Pearson rank correlation coefficient; ^bin all cases the highest ranking correlation was with DTIC; ^cexamples from the 10 top correlations, P values in parentheses. 6TG, 6-thioguanine; 6MP, 6-mercaptopurine; DTIC, dacarbazine.

Table 3. Selected results from NCI60 screen and COMPARE analysis using the log GI₅₀ data as seed in the Standard Agents and Molecular Targets databases.

Further *in vitro* evaluation

The new compounds were further assessed in selected drug-resistant cell lines (Tables 4 and 5). HCT116 is a human colon carcinoma cell line that is deficient in both MGMT and MMR, in consequence it is insensitive to both TMZ and CP.²⁸⁻³⁰ Both mono- and bi-functional agent families showed considerably more potent activity than TMZ and MTZ in this cell line and, in further contrast, activity was retained in the p53-deficient mutant, Table 5. TMZ activity is known to be p53 dependent.³¹ Compounds were also evaluated against an isogenic pair of SNB19 GBM cell lines competent in MMR that either expressed MGMT, SNB19(MGMT), or were negative for MGMT, SNB19(vector). This pair of cell lines highlights the improvements the new bi-functional agents offer over TMZ. The MGMT-proficient line being remarkably insensitive to TMZ (IC₅₀ is unattainable) and the new bi-functional agents showing equivalent activity against the two lines (IC₅₀ 6-12 μ M) with increased potency against both SNB19(vector) and SNB19 (MGMT). A2058 is an aggressive melanoma line that is TMZ-sensitive and even so, the new bi-functional agents show a 10-fold increase in potency.

	A2058	HCT116	SNB19(vector)	SNB19(MGMT)
2g	>100	20.0	77.0	>100
3c	5.5	12.5	11.0	12.0
3e	2.5	5.5	6.6	7.0
TMZ	35.5	>250	37.0	>250

Table 4. IC₅₀ (μ M) for new compounds in selected TMZ-resistant cell lines using the Cyquant Assay (n=2).

	HCT116+/+ ^a	HCT116-/- ^a	Ratio +/+ -/-
2d	55 (8.2)	35.8 (7.1)	1.5
2g	13.2 (14.1)	9.5 (4.8)	1.4
3a	5.5 (1.2)	4.8 (2.1)	1.1
3b	6.2 (n=2)	4.4 (2.7)	1.4
3c	28 (8.1)	17 (5.3)	1.6
3e	7.6 (2.1)	9.9 (n=2)	0.8
MTZ	60 (11.2)	17.9 (8.9)	3.4
CP	11.8 (n=2)	1.9 (2.5)	6.2

Table 5. p53 Independence of chemosensitivity of HCT116 cell lines proficient and deficient in p53. IC₅₀, μ M (SD). ^a IC₅₀ (μ M)

Discussion and Conclusions

The aims of generating new imidazotetrazine prodrugs with activity independent of MGMT and MMR have been achieved through a rationally-designed switch in molecular mechanism. This complements other work, where alternative G06-lesion dependent strategies have been pursued.²⁹ Two new families of mono- and bi-functional 3-anilinoethyl imidazotetrazines have been prepared. These were designed to shift the mechanism of action from dependence on G06-DNA modification to GN7-modification. This was achieved through trapping the diazonium electrophile released on hydrolysis of the imidazotetrazine prodrug as an aziridinium ion. The mono-functional agent **2b** is efficiently converted to an aziridinium ion (Scheme 2) and **2b** and **3b** are both DNA GN7-alkylators.¹⁵ It is proposed, on the basis of analogy with reactive intermediates generated by nitrogen mustard and similar prodrugs, that biological activity is likely associated with this lesion. However it is not yet possible to distinguish definitively between a mechanism of action deriving from GN7-adduct formation and one proceeding from G06-adducts that are resistant to MGMT-mediated repair.

Screening in A2780 and A2780-cp70 cell lines showed that the new compounds are more potent than TMZ. The mono-functional agents are approximately equipotent with MTZ and the bi-functional agents more active. This activity is independent of MGMT activity as determined by use of the MGMT inactivator PaTrin2. Dependence of the IC_{50} on MMR is greatly reduced from approximately 30-fold for TMZ to 2–5-fold for the new bi-functional agents. The Hammett plot, Figure 2, for the bi-functional agents demonstrates the critical rôle of the *para*-substituent in directing the reactivity and bioactivity of the compounds, consistent with the aziridinium ion mechanism occurring *in vitro* and corroborating the design principles. The data identified the *p*-toluidine derivative **3b** as the optimal analog for MGMT and MMR independence and potency.

In the NCI60 screen, the new agents were not uniformly cytotoxic and showed distinct and individual patterns of response over a near 3-log range of GI_{50} . The patterns of biological response to the new agents were distinct from standard agents drawn from the imidazotetrazine, nitrogen mustard and nitrosourea families which, by chemical consideration, may be predicted to share similar mechanisms of action. For all compounds evaluated in the full 60 cell line screen, there was neither correlation with MLH1 or MSH6, nor inverse correlation with MGMT protein expression levels. Correlations in the Molecular Targets database suggest there may be a specific molecular mechanism that accounts for the sensitivity of the leukemia sub-panel to the new agents and, moreover, that activity could be linked to RAS family oncogenes.

Collectively, the *in vitro* data show that the initial aims of improved potency and MGMT and MMR independence have been achieved. The switch of chemical mechanism has resulted in new agents that are distinct from existing imidazotetrazines, nitrogen mustards and nitrosoureas. This implies that an increased diversity of tumor types may now be able to respond to drugs of the imidazotetrazine class. NCI60 panel data identified CP-resistant ovarian carcinoma cell lines as

responsive to the new agents. Chemosensitivity in selected drug-resistant colon carcinoma and glioma cell lines (HCT116 and SNB19) showed that there is activity against TMZ- and CP-resistant tumor lines of these types, and moreover, that the HCT116 response is independent of p53 status. The ability of cells to repair damage by the new agents is linked to the ATR and FANC pathways for the bi-functional and ATM and FANC pathways for mono-functional agents.³² Mutation in one of these genes would hypersensitize a tumour to these new agents.

Overall these findings validate our understanding of the underlying chemistry of imidazotetrazine prodrugs. The members of our compound library are distinctive new agents, worthy of further development and application against a more diverse range of tumor types than TMZ.

Acknowledgement

This work was supported by grant C14492/A4884 from Cancer Research UK. Undergraduate project students M. Haroon Ahmad, Nicholas H. Gunn, Nosheen Hanif, Mobeen Mumtaz, Nazia Nazir, Zaynab Nejadhamzeeigilani and Matthew J. Nelson contributed to the synthetic work. We thank Paul Zavodny and Paul Kirschmeier, Schering-Plough Corp. Kenilworth, NJ for the data in Table 3; Dr Geoff Wells, University College London, for advice on handling NCI data; Xin Ivy Meng and Mohammed U. Saleem, University of Bradford, for the data in Table 5 and some of the data in Figure 1 respectively; Sachin Korde and Amit Sonawane, University of Bradford, for assistance with HPLC.

Experimental

Synthesis

Reagents were purchased from Sigma-Aldrich, Alfa Aesar and Fluka, solvents from Fisher Scientific. TLC was performed on highly-purified silica gel plates with UV indicator (silica gel F₂₄₅), manufactured by Merck and visualized under UV light (366 or 254 nm) or stained with iodine. Melting points were determined with an Electrothermal IA9200 digital melting point apparatus. Infrared data were obtained using a Perkin Elmer (Paragon 1000) FT-IR Spectrophotometer. NMR spectra were acquired on a JEOL GX270 Delta, or where indicated ECA600, spectrometers observing ¹H at 270.05 and 600.17 MHz and ¹³C at 67.80 and 150.91 MHz respectively. ¹³C assignments were made with the aid of the DEPT135 experiment. Mass spectra were obtained from the EPSRC National Mass Spectrometry Service Centre at the University of Swansea, UK, and the Analytical Centre at the University of Bradford using a Micromass Quattro Ultima mass spectrometer. Elemental analyses were obtained from the Advanced Chemical and Material Analysis Unit at the University of Newcastle upon Tyne, UK. All compounds entering biological evaluation were dried *in vacuo* for 3–4 days ≤35 °C; ≥95% purity was adjudged by combustion analysis and hplc, solvation is indicated where appropriate; corresponding analytical hplc chromatograms and highfield ¹H NMR spectra are shown in ESI.

Compounds **2b** and **3b** were prepared as described in reference 15.

Methyl 3-(4-chlorophenylamino)propanoate **12g**

General Method A: Single Conjugate Addition to Anilines.

4-Chloroaniline (20.0 g, 157 mmol) was mixed with methyl acrylate (54.0 g, 627 mmol, 4 eq), cuprous chloride (1.56 g, 15.68 mmol, 0.1 eq) and AcOH (30 mL) and heated under reflux at 160 °C for 2 h. The solvents were removed by evaporation and the residue partitioned between chloroform (500 mL) and water (500 mL). The organic layer was dried (MgSO₄) in the presence of charcoal and filtered through celite. The solvents were removed leaving an oily residue. Petroleum

ether (200 mL) was added and heated to reflux. The solvent was decanted and the product precipitated upon standing. The solid was collected by filtration, washed with petroleum ether and dried to give the ester (23.7 g, 71 %): ^1H NMR (CDCl_3) 7.11 (d, $J = 8.8$ Hz, 2H, 2-H & 6-H), 6.55 (d, $J = 8.8$ Hz, 2H, 3-H & 5-H), 3.68 (OCH_3), 3.41 (t, $J = 7.2$ Hz, 2H, CH_2N), 2.61 (t, $J = 7.2$ Hz, 2H, CH_2CO); ^{13}C NMR (CDCl_3) 172.8 (C=O), 146.1 (C-1), 129.2 (C-2 & C-6), 122.5 (C-4), 114.3 (C-3 & C-5), 51.9 (OCH_3), 39.7 (CH_2N), 33.6 (CH_2CO); MS (ES): m/z 214.1 ($\text{M}+\text{H}$) $^{+}$; IR (film) 3400, 1725, 1600, 1500, 1435 cm^{-1} .

Methyl 3-(methyl(phenyl)amino)propanoate **12a**^{15, 33}

Prepared by General Method A. Ester **12a** was obtained as a colorless oil (13.3 g, 74 %). ^1H NMR (CDCl_3) 7.16 (t, 2H, $J = 8.6$ Hz, 3-H & 5-H), 6.64 (m, 3H, 2-H, 4-H & 6-H), 3.58 (m, 5H, CH_2N & CH_3N), 2.85 (s, 3H, OCH_3), 2.49 (t, $J = 7.3$ Hz, 2H, CH_2CO); ^{13}C NMR (CDCl_3) 172.8 (C=O), 148.6 (C-1), 129.4 (C-3 & C-5), 116.9 (C-4), 112.6 (C-2 & C-6), 51.8 (OCH_3), 48.7 (NCH_2), 38.3 (NCH_3), 31.6 (CH_2CO); MS (ES): m/z 194.1 ($\text{M}+\text{H}$) $^{+}$; ν_{max} (film) 1725s (C=O), 1175m (C-O) cm^{-1} .

Methyl 3-((4-fluorophenyl)(methyl)amino)propanoate **12c**

Prepared according to General Method A. Ester **12c** was obtained as an orange oil (2.22 g, 75%). ^1H NMR (CDCl_3) 6.92 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, m, 2-H & 6-H), 3.65 (s, 3H, OCH_3), 3.60 (t, $J = 7.3$ Hz, 2H, NCH_2), 2.86 (NCH_3), 2.52 (t, $J = 7.3$ Hz, 2H, CH_2CO); ^{13}C NMR (CDCl_3) 172.8 (C=O), 155.7 (d, $^1J_{\text{CF}} = 235$ Hz, C-4), 145.5 (C-1), 115.7 (d, $^2J_{\text{CF}} = 22$ Hz, C-3 & C-5), 114.1 (d, $^3J_{\text{CF}} = 7$ Hz, C-2 & C-6), 51.8 (CH_3O), 49.5 (CH_2N), 38.7 (CH_3N), 31.5 (CH_2CO); MS (ES): m/z 212.1 ($\text{M}+\text{H}$) $^{+}$; IR (KBr) 3025m (Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O) cm^{-1} .

Methyl 3-((4-chlorophenyl)(methyl)amino)propanoate **12d**

Prepared according to General Method A. Ester **12d** was obtained as a yellow oil (9.1 g, 54%). ^1H NMR (CDCl_3) 7.15 (d, $J = 8.9$ Hz, 2H, 3-H & 5-H), 6.63 (d, $J = 8.9$ Hz, 2H, 2-H & 6-H), 3.63 (s,

3H, OCH₃), 3.62 (t, *J* = 7.2 Hz, 2H, NCH₂), 2.89 (s, 3H, NCH₃), 2.54 (t, *J* = 7.2 Hz, 2H, CH₂CO); ¹³C NMR (CDCl₃) 172.6 (C=O), 147.2 (C-1), 129.1 (C-3 & C-5), 121.7 (C-4), 113.9 (C-2 & C-6), 51.9 (OCH₃), 48.8 (NCH₂), 38.4 (NCH₃), 31.5 (CH₂CO); MS (ES): *m/z* 228.1 (M+H)⁺; IR (KBr) 3025m (Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O) cm⁻¹.

Methyl 3-((4-methoxyphenyl)(methyl)amino)propanoate 12e³³

According to General Method A. Ester **12e** was obtained as a colorless oil (4.72 g, 58%): ¹H NMR (CDCl₃) 6.76 (d, 2H, *J* = 9.0 Hz, 3-H & 5-H), 6.67 (d, 2H, *J* = 9.0 Hz, 2-H & 6-H), 3.68 (s, 3H, CH₃O-Ar), 3.59 (s, 3H, CH₃OCO), 3.51 (t, *J* = 7.3 Hz, 2H, CH₂N), 2.78 (s, 3H, CH₃N), 2.46 (t, *J* = 7.3 Hz, 2H, CH₂CO); ¹³C NMR (CDCl₃) 172.4 (C=O), 151.6 (C-4), 143.1 (C-1), 114.6 & 114.3 (C-3, C-5 & C2, C6), 55.3 (CH₃O-Ar), 51.2 (CH₃OCO), 49.4 (NCH₂), 38.4 (CH₃N), 30.9 (CH₂CO); MS (ES): *m/z* 224.1 (M+H)⁺; IR (film) 1725s (C=O), 1175m (C-O) cm⁻¹.

Methyl 3-(*tert*-butoxycarbonyl-(4-chlorophenyl)amino)propanoate 12f

Ester **12g** (2.27 g, 10.6 mmol) was mixed with di-*tert*-butyl carbonate (9.3 g, 42.6 mmol, 4 eq) in the absence of solvent. The mixture was heated at 100 °C for 18 h. The mixture was partitioned between H₂O and petroleum ether. The organic phase was washed with H₂O (5 x 50 mL), dried and evaporated to give ester **4h** as an oil (3.2 g, 97%). ¹H NMR (CDCl₃) 7.29 (d, *J* = 8.8 Hz, 2H, 2-H & 6-H), 7.11 (d, *J* = 8.8 Hz, 2H, 3-H & 5-H), 3.91 (t, *J* = 7.2 Hz, 2H, NCH₂), 3.53 (OCH₃), 2.57 (t, *J* = 7.2 Hz, 2H, CH₂CO), 1.41 (s, 9H, C(CH₃)₃); ¹³C NMR (CDCl₃) 172.3 (OC=O), 154.4 (NC=O), 141.0 (C-1), 130.9 (C-4), 129.1 (C-2 & C-6), 113.7 (C-3 & C-5), 79.8 (C(CH₃)₃), 51.8 (OCH₃), 48.2 (NCH₂), 32.8 (CH₂CO), 28.4 (CH₃); MS (ES): *m/z* 314.1 (M+H)⁺; IR (film) 1725s (C=O), 1175m (C-O) cm⁻¹.

3-(4-Chlorophenylamino)propanehydrazide 13g^{34, 35}

General Method B: Preparation of monohydrazides.

Ester **12g** (3.7 g, 11.8 mmol, 1 eq) was mixed with hydrazine hydrate (5.9 g, 118 mmol, 10 eq) in propan-2-ol (10 mL) for 48h at RT. The volatiles were removed with evaporation to leave hydrazide **13g** as colorless oil (3.5 g, 95%). ^1H NMR (DMSO- d_6) 9.03 (br s, 1H, NHNH_2), 7.05 (d, 2H, $J = 8.9$ Hz, 2-H & 6-H), 6.53 (d, 2H, $J = 8.8$ Hz, 3-H & 5-H), 5.76 (br s, 1H, NH-aniline), 4.28 (s, br, 2H, NH_2), 3.19 (t, $J = 7.2$ Hz, 2H, NCH_2), 2.41 (t, $J = 7.2$ Hz, 2H, CH_2CO); ^{13}C NMR (DMSO- d_6) 170.5 (C=O), 148.0 (C-1), 129.1 (C-3 & C-5), 119.4 (C-4), 113.9 (C-2 & C-6), 39.9 (CH_2N), 33.7 (CH_2CO); MS (ES): m/z 214.1 ($\text{M}+\text{H}$) $^{++}$; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm^{-1} .

3-(Methyl(phenyl)amino)propanehydrazide **13a**

Prepared according to General Method B. Hydrazide **13a** was obtained as a colorless oil (12.7 g, 98%). ^1H NMR (CDCl_3) 7.94 (br s, 1H, NH), 7.20 (t, 2H, $J = 7.8$ Hz, 3-H & 5-H), 6.69 (m, 3H, 2-H, 4-H, 6-H), 3.62 (br, 4H, CH_2N & NH_2), 2.86 (s, 3H, CH_3N), 2.33 (t, $J = 6.8$ Hz, 2H, CH_2CO); ^{13}C NMR (CDCl_3) 172.5 (C=O), 148.7 (C-1), 129.4 (C-3 & C-5), 117.1 (C-4), 112.8 (C-2 & C-6), 49.2 (NCH_2), 38.6 (NCH_3), 31.9 (CH_2CO); MS (ES): m/z 194.1 ($\text{M}+\text{H}$) $^{++}$; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm^{-1} .

3-((4-Fluorophenyl)(methyl)amino)propanehydrazide **13c**

Prepared according to General Method B. Hydrazide **13c** was obtained as a yellow oil (2.16 g, 97%): ^1H NMR (CDCl_3) 7.47 (br s, 1H, NH), 6.91 (m, 2H, 3-H & 5-H), 6.66 (m, 2H, 2-H & 6-H), 3.56 (t, $J = 6.8$ Hz, 2H, CH_2N), 3.5 (br s, 2H, NH_2), 2.83 (s, 3H, NCH_3), 2.34 (t, $J = 6.8$ Hz, 2H, CH_2CO); ^{13}C NMR (CDCl_3) 172.4 (C=O), 156.0 (d, $^1J_{\text{CF}} = 237$ Hz, C-4), 145.6 (C-1), 115.8 (d, $^2J_{\text{CF}} = 22$ Hz, C-3 & C-5), 114.8 (d, $^3J_{\text{CF}} = 8$ Hz, C-2 & C-6), 50.1 (CH_2N), 39.3 (CH_3N), 31.8 (CH_2CO); MS (EI): m/z 212.1 ($\text{M}+\text{H}$) $^{++}$; IR (KBr) 3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm^{-1} .

3-((4-Chlorophenyl)(methyl)amino)propanehydrazide **13d**

Prepared according to General Method B. Hydrazide **13d** was obtained as white solid (4.0 g, 44%): ^1H NMR (CDCl_3) 7.15 (d, 2H, $J = 8.9$ Hz, 3-H & 5-H), 7.03 (s, 1H, NH), 6.62 (d, 2H, $J = 8.9$

Hz, 2-H & 6-H), 3.86 (br s, 2H, NH₂), 3.63 (t, *J* = 6.8 Hz, 2H, CH₂N), 2.88 (s, 3H, NCH₃), 2.35 (t, *J* = 6.8 Hz, 2H, CH₂CO); ¹³C NMR (CDCl₃) 172.2 (C=O), 147.3 (C-1), 129.2 (C-3 & C-5), 122.1 (C-4), 114.0 (C-2 & C-6), 49.3 (NCH₂), 38.8 (NCH₃), 31.8 (CH₂CO); MS (ES): *m/z* 226.9 (M+H)⁺⁺; IR (KBr) 3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm⁻¹.

3-((4-Methoxyphenyl)(methyl)amino)propanehydrazide 13e

Prepared according to General Method B. Hydrazide **13e** was obtained as an oil which crystallized upon standing (4.5 g, 95%): ¹H NMR (CDCl₃) 7.63 (br s, 1H, NH), 6.80 (d, 2H, *J* = 9.2 Hz, 3-H & 5-H), 6.75 (d, 2H, *J* = 9.2 Hz, 2-H & 6-H), 3.72 (s, 3H, CH₃O-Ar), 3.47 (t, *J* = 6.6 Hz, 2H, CH₂N), 3.3 (br s, 2H, NH₂), 2.79 (s, 3H, NCH₃), 2.33 (t, *J* = 6.6 Hz, 2H, CH₂CO); ¹³C NMR (CDCl₃) 172.7 (C=O), 152.9 (C-4), 143.7 (C-1), 116.5 (C-2 & C-6), 114.9 (C-3 & C-5), 55.8 (CH₃O-Ar), 50.7 (CH₂N), 40.0 (NCH₃), 31.9 (CH₂CO); MS (ES): *m/z* 224.1 (M+H)⁺⁺; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm⁻¹.

tert-Butyl-4-chlorophenyl(3-hydrazinyl-3-oxopropyl)carbamate 13f

Prepared according to General Method B. Hydrazide **13f** was obtained as a colorless oil (3.5 g, 95%). ¹H NMR (CDCl₃) 7.76 (br s, 1H, NH), 7.22 (d, 2H, *J* = 7.8 Hz, 2-H & 6-H), 7.04 (d, 2H, *J* = 7.8 Hz, 3-H & 5-H), 3.86 (t, *J* = 6.8 Hz, 2H, NCH₂), 3.65 (s, br, 2H, NH₂), 2.41 (t, *J* = 6.8 Hz, 2H, CH₂CO), 1.41 (s, 9H, C(CH₃)₃); ¹³C NMR (CDCl₃) 173.6 (C=O), 154.3 (NC=O), 141.8 (C-1), 131.1 (C-4), 129.2 (C-2 & C-6), 114.1 (C-3 & C-5), 79.8 (C(CH₃)₃), 48.7 (NCH₂), 34.2 (CH₂CO), 20.3 (ArCH₃); MS (ES): *m/z* 314.1 (M+H)⁺⁺; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm⁻¹.

3-(2-(4-Chlorophenylamino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 2g

General Method C: Preparation of mono-imidazotetrazines

Hydrazide **13g** (1.0 g, 4.68 mmol) was dissolved in dichloromethane (20 mL). Water (20 mL) was added followed by HCl (2.5 mL, 37%). The mixture was cooled in an ice/CaCl₂ bath and a solution of NaNO₂ (0.39 g, 56.2 mmol, 1.2 eq) in water (10 mL) was added with strong agitation at below –5 °C. The ice bath was removed and dichloromethane (20 mL) was added. The reaction mixture was stirred for 40 min and the organic layer was separated, dried over MgSO₄ and evaporated to give the crude azide **14g** as an oil, identified by IR. The oil was diluted with toluene (100 mL) and heated under reflux for 1 h under N₂. The volatile components were removed to give the crude isocyanate **15g** as an oil. Diethylether (150 mL) was added and the mixture heated with strong agitation. The hot ether solution was decanted leaving an oily residue of impurities behind. The ether layer was evaporated to leave pure isocyanate as pale yellow oil (IR ν_{max} 2260s). The isocyanate (0.1 g, 0.48 mmol) was mixed with diazo-IC **5**¹⁸ (0.07 g, 0.48 mmol, 1 eq) in dry DMSO (0.3 mL) under N₂ at RT in the absence of light for 24 h. The reaction was quenched with water (10 mL) and the resultant solid collected by filtration and washed with copious amounts of water to leave imidazotetrazine **2g** as a brown solid (0.16 g, 29%): m.p. 160–161 °C; ¹H NMR (DMSO-d₆, 600 MHz) 8.84 (s, 1H, imidazole CH), 7.82 & 7.70 (2 × br s, 2H, CONH₂), 7.62 (d, *J* = 8.8 Hz, 2H, 3-H & 5-H), 7.54 (d, *J* = 8.8 Hz, 2H, 2-H & 6-H), 4.52 (t, *J* = 6.0 Hz, 2H, NCH₂), 4.42 (t, *J* = 6.0 Hz, 2H, CH₂CO), 3.3 (br s, NH-aniline & H₂O); ¹³C NMR (DMSO-d₆, 151 MHz) 161.8 (C=O amide), 140.0 (C-1), 139.4 (C=O tetrazine), 134.4 (Cq tetrazine), 132.7 (C-4), 131.8 (Cq imidazole), 130.0 (C-3 & C-5), 129.5 (C-H imidazole), 122.3 (C-2 & C-6), 45.9 (CH₂N-aniline), 42.0 (CH₂N-tetrazine); MS (ES): *m/z* 334.1 (M+H)⁺; IR (KBr) 3450m & 3300 (CONH₂), 1750s (C=O), 1650s (CONH₂), 1600m & 1500s (Ar-H) cm⁻¹. Anal. C₂₀H₁₉N₁₃O₄·0.25H₂O, CHN.

3-(2-(Methyl(phenyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 2a

Prepared according to General Method C. The product was purified by flash column chromatography (2% MeOH/CHCl₃) and imidazotetrazine **2a** was obtained as a white solid (0.34 g, 21%): m.p. 186–187 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.77 (s, 1H, imidazole CH), 7.79 & 7.68 (2

× br s, 2H, CONH₂), 7.06 (t, *J* = 8.6 Hz, 2H, 3-H & 5-H), 6.68 (d, *J* = 8.6 Hz, 2H, 2-H & 6-H), 6.50 (t, *J* = 8.6 Hz, 1H, 4-H), 4.46 (t, *J* = 6.4 Hz, 2H, NCH₂), 3.80 (t, *J* = 6.4 Hz, 2H, CH₂CO), 2.91 (s, 3H, NCH₃); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (CONH₂), 148.9 (C-1), 139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.4 (C-3 & C-5), 129.2 (C-H imidazole), 116.6 (C-4), 112.4 (C-2 & C-6), 50.3 (CH₂N-aniline), 46.4 (CH₂N-tetrazine), 38.3 (CH₃); MS (ES): *m/z* 314.2 (M+H)⁺⁺; 627.4 (2M+H)⁺⁺; IR (KBr) 3450m (CONH₂), 1750s (C=O), 1675s (CONH₂), 1600m (Ar-H) cm⁻¹.
 Anal. C₁₄H₁₅N₇O₂, CHN.

3-(2-((4-Chlorophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 2d

Prepared by General Method C. The product was precipitated with water, collected by filtration and the crude solid dried and suspended in chloroform (20 mL). The impurities were removed by filtration and the filtrate evaporated to yield imidazotetrazine **2d** as a yellow solid (0.084 g, 25%): m.p. 154–155 °C ¹H NMR (DMSO-d₆, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.75 & 7.65 (2 × br s, 2H, CONH₂), 7.07 (d, *J* = 8.8 Hz, 2H, 3-H & 5-H), 6.66 (d, *J* = 8.8 Hz, 2H, 2-H & 6-H), 4.43 (t, *J* = 6.6 Hz, 2H, CH₂N), 3.77 (t, *J* = 6.6 Hz, 2H, CH₂CO), 2.87 (s, 3H, NCH₃); ¹³C NMR (151 MHz, DMSO-d₆) 161.9 (CONH₂), 147.8 (C-1), 139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq imidazole), 129.2 (C-H imidazole), 129.1 (C-3 & C-5), 120.3 (C-4), 113.9 (C-2 & C-6), 50.4 (CH₂N-aniline), 46.3 (CH₂N-tetrazine), 38.5 (CH₃); MS (ES): *m/z* 348.2 (M+H)⁺⁺; 695.3 (2M+H)⁺⁺; 717.3 (2M+Na)⁺⁺; IR (KBr) 3450m (CONH₂), 1750s (C=O), 1675s (CONH₂), 1600m & 1500s (Ar-H) cm⁻¹.
 Anal. C₁₄H₁₄ClN₇O₂·0.5 H₂O, CHN.

tert-Butyl 2-(8-carbamoyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazin-3(4H)-yl)ethyl(4-chlorophenyl) carbamate 2f

Prepared according to General Method C. The product was purified by flash column chromatography (10% AcOH/CHCl₃) and imidazotetrazine **2f** was obtained as a white solid (0.15 g, 51%): m.p. 177–178 °C; ¹H NMR (DMSO-d₆, 600 MHz) 8.91 (s, 1H, imidazole CH), 7.83 & 7.70 (2

× br s, 2H, CONH₂), 7.40 (d, *J* = 8.8 Hz, 2H, 3-H & 5-H), 7.32 (d, *J* = 8.8 Hz, 2H, 2-H & 6-H), 4.40 (t, *J* = 6.7 Hz, 2H, NCH₂), 4.04 (t, *J* = 6.5 Hz, 2H, CH₂CO), 1.11 (s, 9H, C(CH₃)₃); ¹³C NMR (DMSO-d₆, 151 MHz) 161.8 (CONH₂), 154.3 (N(CO)O), 140.8 (C-1), 139.6 (CO tetrazine), 134.6 (Cq tetrazine), 131.4 (Cq imidazole), 131.0 (C-4), 129.4 (C-H imidazole), 129.2 & 129.1 (C-3 & C-5, C-2 & C-6), 80.74 (C(CH₃)₃), 48.3 & 48.0 (CH₂N-tetrazine & CH₂N-aniline), 28.0 (CH₃); MS (ES): *m/z* 434.3 (M+H)⁺⁺; 456.2 (M + Na)⁺⁺; IR (KBr) 3450m (CONH₂), 3150m (CONH₂), 1750s (C=O), 1700s (CONH₂), 1600m & 1500s (Ar-H) cm⁻¹. Anal. C₁₈H₂₀ClN₇O₄·¹/₃ H₂O, CHN.

3-(2-(Methyl(4-methyl-3-nitrophenyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 2h

Prepared according to General Method C from hydrazide **13b**. On completion of the reaction, the mixture was quenched with propan-2-ol (10 mL) and the solid collected by filtration and washed with propan-2-ol then methanol to leave imidazotetrazine **2h** as an orange solid (0.43 g, 24%): m.p. 133–134 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.76 (s, 1H, imidazole CH), 7.77 & 7.66 (2 × br s, 2H, CONH₂), 7.38 (d, *J* = 2.0 Hz, 1H, 2-H), 7.20 (d, *J* = 8.4 Hz, 1H, 5-H), 7.14 (br d, *J* = 8.4 Hz, 1H, 6-H), 4.44 (t, *J* = 6.2 Hz, 2H, CH₂N-aniline), 3.45 (t, *J* = 6.2 Hz, 2H, CH₂N-tetrazine), 2.75 (s, 3H, NCH₃), 2.12 (s, 3H, ArCH₃); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (CONH₂), 143.0 (C-3), 142.5 (C-1), 139.4 (C=O tetrazine), 134.6 (Cq tetrazine), 134.3 (C-2), 131.4 (Cq imidazole), 131.3 (C-4), 129.2 (C-H imidazole), 125.3 (C-6), 121.8 (C-5), 53.4 (CH₂N-aniline), 46.4 (CH₂N-tetrazine), 40.7 (CH₃N), 20.0 (ArCH₃); MS (ES): *m/z* 373.2 (M+H)⁺⁺; 395.2 (M + Na)⁺⁺. Anal. C₁₅H₁₆N₈O₄·0.15 H₂O, CHN.

3-(2-((4-Methoxy-2-nitrophenyl)(methyl)amino)ethyl)-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide 2i

Prepared according to General Method C from **13e**. The product was purified by flash column chromatography (10% AcOH/CHCl₃). The solid was washed with 50% MeOH/H₂O and imidazotetrazine **2i** was obtained as a purplish red solid (0.21 g, 26%): m.p. 166–168 °C. ¹H NMR

(DMSO- d_6 , 600 MHz) 8.80 (s, 1H, imidazole CH), 7.79 & 7.67 (2 $\times$ br s, 2H, CONH₂), 7.36 (d, J = 8.9 Hz, 1H, 6-H), 7.18 (d, J = 3.0 Hz, 1H, 3-H), 7.07 (dd, J = 3.0, 8.9 Hz, 1H, 5-H), 4.42 (t, J = 6.0 Hz, 2H, CH₂N-aniline), 3.68 (s, 3H, OCH₃) 3.35 (t, J = 6.0 Hz, 2H, CH₂N-tetrazine), 2.70 (s, 3H, NCH₃); ¹³C NMR (DMSO- d_6 , 151 MHz) 162.0 (CONH₂, 155.2 (C-4), 145.8 (C-2), 139.4 (C=O tetrazine), 138.6 (C-1), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.2 (C-H imidazole), 125.1 (C-6), 119.9 (C-3), 108.9 (C-5), 56.4 (CH₃O), 54.5 (CH₂N-aniline), 46.6 (CH₂N-tetrazine), 42.0 (NCH₃); MS (ES): m/z 389.2 (M+H)⁺; 411.2 (M + Na)⁺; IR (KBr) 3425m (CONH₂), 3150m (CONH₂), 1750s (C=O), 1700s (CONH₂), 1600m & 1525s (Ar-H) cm⁻¹. Anal. C₁₅H₁₆N₈O₅·0.1 H₂O, CHN.

Modified Procedure for tetrazine 2c

3-(2-(*N*-(4-Fluorophenyl)-*N*-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide 2c

3-(*N*-(4-Fluorophenyl)-*N*-methylamino)propanoyl azide 14c

Hydrazide **13c** (0.25 g, 1.2 mmol) was dissolved in a mixture of AcOH (0.66M 15 mL) and DCM (15 mL), the mixture was then stirred on a CaCl₂-ice bath at 0 °C, a solution of NaNO₂ (0.49 g, 7.1 mmol) in H₂O (25 mL) was added dropwise keeping the exothermic reaction at 0–5 °C. A further amount of DCM (20 mL) was added, the DCM layer separated, washed with H₂O (20 mL) dried over MgSO₄, then filtered. Formation of azide **14c** was confirmed by IR. ¹H NMR (CDCl₃, 600 MHz): 6.93 (t, 2H, J_{HH} = $^3J_{HF}$ = 9.1 Hz, 3',5'-H), 6.66 (dd, 2H, J_{HH} = 9.1 Hz, $^4J_{HF}$ = 4.3 Hz, 2',6'-H), 3.60 (t, 2H, J = 7.1 Hz, 3-H), 2.86 (s, 3H, NCH₃), 2.55 (t, 2H, J = 7.1 Hz, 2-H); ¹³C NMR (CDCl₃, 151 MHz) 179.2 (C-1), 155.3 (d, $^1J_{CF}$ = 237 Hz, C-4'), 145.2 (C-1'), 115.8 (d, $^2J_{CF}$ = 21.7 Hz, C-3',5'), 114.3 (d, $^3J_{CF}$ = 7.2 Hz, C-2',6'), 49.4 (C-3), 38.9 (NCH₃), 34.2 (C-2); IR (liq. film) 2914w (CH st), 2137s (CON₃), 1711s (CO), 1511m (C=C), 815s (*p*-di-substituted aromatic ring) cm⁻¹.

2-(*N*-(4-Fluorophenyl)-*N*-methylamino)ethyl isocyanate 15c

The anhydrous DCM solution of azide **14c** was stirred under nitrogen at RT overnight. Isocyanate **15c** formation was confirmed by IR and ^1H NMR. The DCM was evaporated under reduced pressure at low temperature (an ice bath was used to lower the temperature). The isocyanate was collected as a yellow oil (0.2 g, 77%). ^1H NMR (CDCl_3 , 600 MHz) 6.95 (t, 2H, $J_{HH} = {}^3J_{HF} = 9.1$ Hz, 3',5'-H), 6.69 (dd, 2H, $J_{HH} = 9.1$ Hz, ${}^4J_{HF} = 4.3$ Hz, 2',6'-H), 3.43 (m, 4H, 1,2-H), 2.94 (s, 3H, NCH_3); ^{13}C NMR (CDCl_3 , 151 MHz) 157.2 (NCO), 155.3 (d, ${}^1J_{CF} = 237$ Hz, C-4'), 145.2 (C-1'), 115.8 (d, ${}^2J_{CF} = 21.7$ Hz, C-3',5'), 114.4 (d, ${}^3J_{CF} = 7.2$ Hz, C-2',6'), 54.5 (C-3), 40.9 (C-2), 39.6 (NCH_3); IR (liq film) 3057w (Ar-CH st), 2917w (CH st), 2270s (NCO), 1512m (C=C), 1228m, 816s (*p*-di-substituted aromatic ring) cm^{-1} ; MS (ES) m/z 195 (100%) ($\text{M}+\text{H}$) $^+$.

3-(2-(*N*-(4-Fluorophenyl)-*N*-methylamino)ethyl)-4-oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide **2c**

Isocyanate **15c** (0.2 g, 1.03 mmol) was diluted with DMSO (1.5 mL) under nitrogen then added to a suspension of diazo-IC **5** (0.14 g, 1.03 mmol) in DMSO (1.5 mL), the mixture was stirred at rt protected from light for 48 h. The ^1H NMR spectrum showed product **2c** formation. The reaction mixture was suspended in H_2O (30 mL) and filtered, the residue was washed with copious amounts of H_2O until the washings came through colorless and then washed with Et_2O . The solid was purified by flash column chromatography, 10% AcOH in CHCl_3 was used for the elution; the fractions containing the product were evaporated to give an orange solid. The solid was then re-dissolved in CHCl_3 and filtered, the CHCl_3 evaporated and the residue re-suspended in Et_2O and then collected by filtration to give **2c** (0.057 g, 17%), m.p. 172–173 °C. ^1H NMR ($\text{DMSO}-d_6$, 600 MHz): 8.77 (s, 1H, 6-H), 7.75 & 7.65 (2 $\times$ br s, 2H, CONH_2), 6.91 (t, 2H, $J_{HH} = J_{HF} = 9.1$ Hz, 3',5'-H), 6.69 (dd, 2H, $J_{HH} = 9.1$ Hz, $J_{HF} = 4.3$ Hz, 2',6'-H), 3.45 (t, 2H, $J = 6.4$ Hz, 1-H), 3.77 (t, 2H, $J = 6.4$ Hz, 2-H), 2.90 (s, 3H, NCH_3); ^{13}C NMR (CDCl_3 , 151 MHz) 161.89 (CONH_2), 155.0 (d, ${}^1J_{CF} = 235.5$ Hz, C-4'), 145.9 (C-1'), 139.5 (C-4), 134.7 (C-8a), 131.3 (C-8), 129.2 (C-6), 115.7 (d, ${}^2J_{CF} = 21.7$ Hz, C-3',5'), 113.6 (d, ${}^3J_{CF} = 7.2$ Hz, C-2',6'), 50.9 (C-2), 46.3 (C-1) 38.7 (NCH_3); IR (KBr) 3439s (NH), 3117m (Ar-CH st), 2914w (CH st), 1749s (C(4)O), 1682s (CONH_2), 1515 s, 1458m (C=C),

820m (*p*-di-substituted aromatic ring) cm^{-1} ; MS (ES): m/z 331.9 (20%) $(\text{M}+\text{H})^+$, 353.9 (10%) $(\text{M}+\text{Na})^+$, 195.0 (100%) $(\text{C}_{10}\text{H}_{11}\text{FN}_2\text{O}+\text{H})^+$. Anal. $\text{C}_{14}\text{H}_{14}\text{FN}_7\text{O}_2 \cdot 0.75\text{H}_2\text{O}$, CHN.

Modified Procedure for tetrazine 2e

3-(*N*-Methyl-*N*-(4-nitrophenyl)amino)propanoyl azide 14e and

3(*N*-methyl-*N*-(2-nitrophenyl)amino)propanoyl azide

Hydrazide **13a** (0.3g, 1.6 mmol) was dissolved in a mixture of DCM (10 mL) and HCl (10 mL, 14.8%), the solution was stirred at 0 °C on a CaCl_2 -ice bath, NaNO_2 (0.66 g, 9.6 mmol) solution in H_2O (10 mL) was added gradually, keeping the exothermic reaction between 0–5 °C. A further portion of DCM (15 mL) was added, the DCM layer was separated, washed with two portions of H_2O (20 mL) dried over MgSO_4 , then filtered. Formation of the azide **14e** was confirmed by IR and ^1H NMR which also showed the formation of small amount of the *ortho*-nitrated azide in ratio 1:5. Azide **14e** ^1H NMR (CDCl_3 , 600 MHz) 8.12 ($\frac{1}{2}\text{AB}$, 2H, $J = 9.5$ Hz, 3',5'-H), 6.61 ($\frac{1}{2}\text{AB}$, 2H, $J = 9.5$ Hz, 2',6'-H), 3.77 (t, 2H, $J = 7.0$ Hz, 3-H), 3.10 (s, 3H, NCH_3) 2.62 (t, 2H, $J = 7.0$ Hz, 2-H); ^{13}C NMR (CDCl_3) δ : 178.5 (CON_3), 152.8 (C-4'), 133.2 (C-1'), 126.4 (C-3',5'), 110.6 (C-2',6'), 48.0 (C-3), 39.1 (NCH_3), 34.4 (C-2); IR (liq film) 2918w (CH st), 2140s (N_3), 1711s (CO), 1597s (NO_2 st as), 1518 s (C=C), 1311s (NO_2 st) cm^{-1} . ***o*-NO₂-Azide:** ^1H NMR (CDCl_3 , 600 MHz): 7.72 (d, 1H, $J = 8.9$ Hz, 5'-H), 7.42 (t, 1H, $J = 8.9$ Hz, 4'-H), 7.21 (d, 1H, $J = 8.9$ Hz, 2'-H), 6.96 (t, 1H, $J = 8.9$ Hz, 3'-H), 3.46 (t, 2H, $J = 7.1$ Hz, 3-H), 2.80 (s, 3H, NCH_3) 2.62 (t, 2H, $J = 7.1$ Hz, 2-H).

2-[(4-Nitrophenyl)methylamino]ethylisocyanate 15e

The anhydrous DCM solution of the crude azide **14e** was stirred under nitrogen at RT overnight. Isocyanate formation was confirmed by IR. The DCM was evaporated under reduced pressure at low temperature (an ice bath was used to lower the temperature) and the crude isocyanate **15e** collected as a yellow oil (0.27 g, 90 %). ^1H NMR (CDCl_3 , 600 MHz) 8.15 ($\frac{1}{2}\text{AB}$, 2H, $J = 9.4$ Hz, 3',5'-H), 6.67 ($\frac{1}{2}\text{AB}$, 2H, $J = 9.4$ Hz, 2',6'-H), 3.66 (t, 2H, $J = 6.2$ Hz, 2-H), 3.57 (t, 2H, $J = 6.2$ Hz, 1-

H), 3.15 (s, 3H, NCH₃); ¹³C NMR (CDCl₃, 151 MHz) 153.1 (NCO), 145.2 (C-4'), 138.1 (C-1'), 126.4 (C-3',5'), 110.7 (C-2',6'), 52.6 (C-2), 40.7 (C-1), 39.5 (NCH₃); IR (liq film) 2919w (CH st), 2270s (NCO), 1597s (NO₂ st as), 1517 s (C=C), 1311s (NO₂ st) cm⁻¹. **Isocyanate *ortho*-nitro isomer:** ¹H NMR (CDCl₃, 600 MHz) 7.74 (d, 1H, *J* = 8.4 Hz, 5'-H), 7.45 (t, 1H, *J* = 8.4 Hz, 4'-H), 7.18 (d, 1H, *J* = 8.4 Hz, 2'-H), 6.99 (t, 1H, *J* = 8.9 Hz, 3'-H), 3.48 (t, 2H, *J* = 6.0 Hz, 3-H), 2.90 (s, 3H, NCH₃), 3.31 (t, 2H, *J* = 7.1 Hz, 2-H).

3-(2-*N*-Methyl-*N*-(4-nitrophenyl)-*N*-methylanino)ethyl)-4-oxo-3H,4H-imidazo[1,5-d][1,2,3,5]tetrazine-8-carboxamide **2e and**

3-(2-(*N*-methyl-*N*-(2-nitrophenyl)-*N*-methylanino)ethyl)-4-oxo-3H,4H-imidazo[5,1d][1,2,3,5]tetrazine-8-carboxamide

The crude mixture of the isocyanate **15e** (0.27 g, 1.22 mmol) was diluted with DMSO (1.5 mL) under N₂ then added to a suspension of diazo-IC **5** (0.17 g, 1.22 mmol) in DMSO (1.5 mL), the mixture was stirred at RT protected from light for 48 h. The reaction mixture was then suspended in water (30 mL) and filtered. The solid on the filter was washed with copious amounts of H₂O until the washings came through colorless, then with Et₂O. The dry solid was purified by flash column chromatography eluted with a gradient 5–20% AcOH in CHCl₃. ¹H NMR showed impurities from silica, so the imidazotetrazinone solid was dissolved in DMF, filtered and the imidazotetrazinone precipitated as a yellow solid by H₂O addition. The solid was collected by filtration, washed with copious amounts of water and then dried to give **2e** (0.025g, 6 %), m.p. 179–180 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.81 (s, 1H, 6-H), 8.00 (½AB, 2H, *J* = 9.2 Hz, 3',5'-H), 7.77 & 7.67 (2 × br s, 2H, CONH₂), 6.82 (½AB, 2H, *J* = 9.2 Hz, 2',6'-H), 4.52 (t, 2H, *J* = 6.3 Hz, 1-H), 3.96 (t, 2H, *J* = 6.3 Hz, 2-H), 3.07 (s, 3H, NCH₃); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (CONH₂), 154.0 (C-4'), 139.7 (C-4), 136.6 (C-1'), 134.7 (C-8a), 131.6 (C-8), 129.5 (C-6), 126.3 (C-3',5'), 111.4 (C-2',6'), 50.3 (C-2), 46.4 (C-1) 39.2 (NCH₃); IR (KBr) 3443m (NH), 2919w (CH st), 1749s (C(4)O), 1684s (CONH), 1597s (NO₂ st as), 1457m (C=C), 1316s (NO₂ st) cm⁻¹; MS(ES): *m/z* 359.1(80%) (M+H)⁺, 381.1(100%) (M+Na)⁺; Anal. C₁₄H₁₄N₈O₄ · 0.6 AcOH · 0.2 CHCl₃, CHN.

meta-NO₂ isomer: ¹H NMR (DMSO-d₆, 600 MHz) 8.83 (s, 1H, 6-H), 7.83 & 7.71 (2 × br s, 2H, CONH₂), 7.65 (d, 1H, *J* = 9.1 Hz, 5'-H), 7.46 (t, 1H, *J* = 9.1 Hz, 4'-H), 7.31 (t, 1H, *J* = 9.1 Hz, 2'-H), 6.92 (d, 1H, *J* = 9.1 Hz, 3'-H), 4.52 (t, 2H, *J* = 6.1 Hz, 1-H), 3.59 (t, 2H, *J* = 6.1 Hz, 2-H), 2.83 (s, 3H, NCH₃).

Dimethyl 3,3'-(4-chlorophenylazanediyl)dipropionate 8d³⁶

General Method D: Double Conjugate addition to anilines.

4-Chloroaniline (10 g, 78.4 mmol) was mixed with methyl acrylate (67.5 g, 784 mmol, 10 eq), cuprous chloride (1.24 g, 12.5 mmol, 0.16 eq) and AcOH (100 mL) and heated under reflux at 140 °C for 48 h. The reaction mixture was allowed to reach RT and water (300 mL) was added with strong agitation. The batch was allowed to stand in the fridge overnight and the water layer was decanted leaving the oil behind. The oil was washed with more water (2 × 300 mL), diluted with diethylether (200 mL), washed with water (300 mL), dried over MgSO₄ and evaporated to give diester **8d** as a light brown oil (19.0 g, 88%). ¹H NMR (CDCl₃) 7.17 (d, *J* = 8.8 Hz, 2H, 3-H & 5-H), 6.68 (d, *J* = 8.8 Hz, 2H, 2-H & 6-H), 3.65 (s, 6H, 2 × CH₃), 3.61 (t, *J* = 7.2 Hz, 4H, 2 × CH₂N), 2.57 (t, *J* = 7.2 Hz, 4H, 2 × CH₂CO); ¹³C NMR (CDCl₃) 172.3 (C=O), 145.0 (C-1), 129.4 (C-3 & C-5), 129.3 (C-4), 114.1 (C-2 & C-6), 51.9 (CH₃), 47.2 (NCH₂), 32.1 (CH₂CO); MS (ES): *m/z* 300.1 (M+H)⁺; IR (film) 1725s (C=O), 1175m (C-O) cm⁻¹.

Dimethyl 3,3'-(phenylazanediyl)dipropionate 8a³⁷

Prepared according to General method D. Diester **8a** was obtained as an orange oil (18.8 g, 67%). ¹H NMR (CDCl₃) 7.16 (m, 2H, 3-H & 5-H), 6.62 (m, 3H, 2-H, 4-H, 6-H), 3.60 (m, 10H, 2 × CH₂N-aniline & 2 × OCH₃), 2.52 (t, *J* = 7.1 Hz, 4H, 2 × CH₂CO); ¹³C NMR (CDCl₃) 172.6 (C=O), 146.7 (C-1), 129.6 (C-3 & C-5), 117.2 (C-4), 112.6 (C-2 & C-6), 51.8 (CH₃), 47.0 (NCH₂), 32.3 (CH₂CO); MS (ES): *m/z* 266.1 (M+H)⁺; IR (film) 1725s (C=O), 1175m (C-O) cm⁻¹.

Dimethyl 3,3'-(4-fluorophenylazanediyl)dipropionate 8c³⁷ Prepared according to General Method D. Diester **8c** was obtained as a yellow oil (0.99 g, 75%). ¹H NMR (CDCl₃) 6.92 (m, 2H, 3-H & 5-H), 6.74 (m, 2H, 2-H & 6-H), 3.64 (s, 6H, 2 x CH₃), 3.56 (t, *J* = 7.2 Hz, 4H, 2 x CH₂N), 2.52 (t, *J* = 7.2 Hz, 4H, 2 x CH₂CO); ¹³C NMR (CDCl₃) 172.6 (C=O), 156.0 (d, ¹*J*_{CF} = 237 Hz, C-4), 143.5 (C-1), 115.9 (d, ²*J*_{CF} = 22 Hz, C-3 & C-5), 114.9 (d, ³*J*_{CF} = 7 Hz, C-2 & C-6), 51.8 (CH₃), 47.7 (CH₂N), 32.3 (CH₂CO); ¹⁹F NMR (CDCl₃) -127.62; MS (ES): *m/z* 284.0 (M+H)⁺⁺; IR (KBr) 3025m (Ar C-H), 2950m (C-H), 1725s (C=O), 1525m (Ar C=C), 1175m (C-O), cm⁻¹.

Dimethyl 3,3'-(4-methoxyphenylazanediyl)dipropionate 8e³⁷

Prepared according to General Method D. Diester **8e** was obtained as an orange oil (21.7 g, 90%). ¹H NMR (CDCl₃) 6.84 (d, 2H, *J* = 8.1 Hz, 3-H & 5-H), 6.74 (d, 2H, *J* = 8.1 Hz, 2-H & 6-H), 3.75 (s, 3H, CH₃), 3.64 (s, 6H, 2 x CH₃), 3.53 (t, *J* = 7.1 Hz, 4H, 2 x NCH₂), 2.51 (t, *J* = 7.1 Hz, 4H, 2 x CH₂CO); ¹³C NMR (CDCl₃) 175.4 (C=O), 152.9 (C-4), 141.0 (C-1), 121.4 (C-3 & C-5), 114.9 (C-2 & C-6), 55.8 (CH₃), 51.9 (CH₃), 50.5 (NCH₂), 33.5 (CH₂CO); MS (ES): *m/z* 296.1 (M+H)⁺⁺; IR (film) 1725s (C=O), 1175m (C-O) cm⁻¹.

3,3'-(4-Chlorophenylazanediyl)dipropanehydrazide 10d

General Method E: Preparation of bis-hydrazides

Diester **8d** (19 g, 63.4 mmol) was mixed with hydrazine hydrate (12.6 g, 0.25 mol, 4 eq) in propan-2-ol (60 mL) for 48 h at RT. The resulting solid was collected by filtration, washed with propan-2-ol and dried *in vacuo* to give hydrazide **10d** as white solid (18.8 g, 99%): ¹H NMR (DMSO-d₆) 9.03 (s, 2H, 2 x NH), 7.15 (d, 2H, *J* = 9.1 Hz, 3-H & 5-H), 6.66 (d, 2H, *J* = 9.1 Hz, 2-H & 6-H), 4.18 (br s, 4H, 2 x NH₂), 3.46 (t, *J* = 7.2 Hz, 4H, 2 x NCH₂), 2.23 (t, *J* = 7.2 Hz, 4H, 2 x CH₂CO); ¹³C NMR (DMSO-d₆) 170.4 (C=O), 146.4 (C-1), 129.3 (C-3 & C-5), 119.8 (C-4), 113.8 (C-2 & C-6), 47.4 (NCH₂), 31.9 (CH₂CO); MS (ES): *m/z* 300.1 (M+H)⁺⁺; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm⁻¹.

3,3'-(Phenylazanediyl)dipropanehydrazide 10a³⁸

Prepared according to General Method E. Hydrazide **10a** was obtained as a white solid (6.3 g, 72%). ¹H NMR (DMSO) 9.04 (s, 2H, 2 x NH), 7.15 (t, 2H, *J* = 7.4 Hz, 3-H & 5-H), 6.66 (d, 2H, *J* = 7.4 Hz, 2-H & 6-H), 6.58 (t, 2H, *J* = 7.4 Hz, 4-H), 4.18 (br s, 4H, 2 x NH₂), 3.48 (t, *J* = 7.2 Hz, 4H, 2 x CH₂N), 2.25 (t, *J* = 7.2 Hz, 4H, 2 x CH₂CO); ¹³C NMR (DMSO) 170.5 (C=O), 147.6 (C-1), 129.7 (C-3 & C-5), 116.2 (C-4), 112.4 (C-2 & C-6), 47.4 (NCH₂), 32.1 (CH₂CO); MS (ES): *m/z* 266.1 (M+H)⁺⁺; IR (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm⁻¹.

3,3'-(4-Fluorophenylazanediyl)dipropanehydrazide 10c

Prepared according to General Method E. Hydrazide **10c** was obtained as a white solid (0.63 g, 64%): m.p. 131.4 °C. ¹H NMR (DMSO-d₆) 8.91 (br s, 2H, 2 x NH), 6.88 (m, 2H, 3-H & 5-H), 6.56 (m, 2H, 2-H & 6-H), 4.07 (br s, 4H, 2 x NH₂), 3.33 (t, *J* = 7.2 Hz, 4H, 2 x CH₂N), 2.11 (t, *J* = 7.2 Hz, 4H, 2 x CH₂CO); ¹³C NMR (DMSO-d₆) 170.5 (C=O), 154.8 (d, ¹*J*_{CF} = 228 Hz, C-4), 144.5 (C-1), 116.0 (d, ²*J*_{CF} = 22 Hz, C-3 & C-5), 113.7 (d, ³*J*_{CF} = 7 Hz, C-2 & C-6), 47.8 (CH₂N), 31.9 (CH₂CO); ¹⁹F NMR (CDCl₃) -129.53; MS (EI): *m/z* 283.0 (M+H)⁺⁺; ν_{max} (KBr) 3300m (NH), 3050m (Ar C-H), 1650s (CONH), 1525m (Ar C=C) cm⁻¹

3,3'-(4-Methoxyphenylazanediyl)dipropanehydrazide 10e

Prepared according to General Method E. Hydrazide **10e** was obtained as a white solid (20.5 g, 95%): ¹H NMR (CDCl₃) 7.39 (br s, 2H, 2 x NH), 6.85 (d, 2H, *J* = 8.1 Hz, 3-H & 5-H), 6.80 (d, 2H, *J* = 8.1 Hz, 2-H & 6-H), 4.10 (br s, 4H, 2 x NH₂), 3.75 (s, 3H, CH₃), 3.32 (t, *J* = 7.1 Hz, 4H, 2 x CH₂N), 2.28 (t, *J* = 7.1 Hz, 4H, 2 x CH₂CO); ¹³C NMR (CDCl₃) 173.4 (C=O), 155.0 (C-4), 142.4 (C-1), 121.4 (C-3 & C-5), 114.7 (C-2 & C-6), 55.6 (CH₃), 50.7 (NCH₂), 33.3 (CH₂CO); MS (ES): *m/z* 296.1 (M+H)⁺⁺; ν_{max} (KBr) 3300s (NH), 3050m (Ar C-H), 1650s (CONH) cm⁻¹.

3,3'-(2,2'-(4-Chlorophenylazanediyl))bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3d

General Method F: Preparation of bis-imidazotetrazines

Hydrazide **10d** (1.0 g, 3.18 mmol, 1 eq) was dissolved in dichloromethane (10 mL). Water (10 mL) was added followed by HCl (2.5 mL, 37 %). The mixture was cooled in an ice/CaCl₂ bath and a solution of NaNO₂ (0.57 g, 8.26 mmol, 2.6 eq) in water (10 mL) was added with strong agitation below 5 °C. After the addition, the reaction was allowed to reach RT and stirred overnight. The organic layer was separated, dried over MgSO₄ and evaporated to give the azide **11d** as a crude oil, identified by IR. The oil was diluted with toluene (100 mL) and heated under reflux for 2 h under N₂. The volatile components were removed to give the crude isocyanate **9d** as an oil. Diethylether (150 mL) was added and the mixture heated with strong agitation. The hot solution was decanted leaving a residue of oily impurities behind. The ether was evaporated to leave pure isocyanate as pale yellow oil (IR $\nu_{\max}$ 2260s). The isocyanate (0.29g, 1.03 mmol) was mixed with diazo-IC **5** (0.3 g, 2.17 mmol, 2.1 eq) in dry DMSO (0.1 mL) under N₂ at RT in the absence of light for 24 h. The bis-imidazotetrazine was purified by flash column chromatography eluting with CHCl₃:AcOH (1:1) to give imidazotetrazine **3d** as a light brown solid (0.1 g, 6%): m.p. 143-144 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 (2 × br s, 4H, 2 × CONH₂), 7.09 (d, *J* = 8.9 Hz, 2H, 3-H & 5-H), 6.80 (d, *J* = 8.9 Hz, 2H, 2-H & 6-H), 4.42 (t, *J* = 6.6 Hz, 4H, 2 × NCH₂ aniline), 3.78 (t, *J* = 6.6 Hz, 4H, 2 × CH₂N-tetrazine); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (C=O amide), 146.2 (C-1), 140.0 (C=O tetrazine), 134.7 (Cq tetrazine), 131.4 (Cq imidazole), 2 × 129.3 (C-3 & C-5, C-H imidazole), 120.9 (C-4), 114.2 (C-2 & C-6), 49.1 (CH₂N-aniline), 46.4 (CH₂N-tetrazine); MS (ES): *m/z* 540.2 (M+H)⁺⁺; 562.3 (M + Na)⁺⁺; IR (KBr) 3450m (CONH₂), 1750s (C=O), 1675s (CONH₂), 1600m & 1500s (Ar-H) cm⁻¹. Anal. C₂₀H₁₈ClN₁₃O₄·0.85 AcOH, CHN.

3,3'-(2,2'-(Phenylazanediyl))bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3a

Prepared according to General Method F. The product was purified by flash column chromatography (5% AcOH/CH₃CN) and imidazotetrazine **3a** was obtained as a yellow solid (0.38 g, 60%): m.p. 194–195 °C; ¹H NMR (DMSO-d₆, 600 MHz) 8.79 (s, 2H, imidazole CH), 7.77 & 7.66 (2 × br s, 4H, 2 × CONH₂), 7.06 (t, *J* = 7.5 Hz, 2H, 3-H & 5-H), 6.80 (d, *J* = 7.5 Hz, 2H, 2-H & 6-H), 6.51 (t, *J* = 7.5 Hz, 1H, 4-H), 4.44 (t, *J* = 6.9 Hz, 4H, 2 × CH₂N-aniline), 3.79 (t, *J* = 6.9 Hz, 4H, 2 × CH₂N-tetrazine); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (C=O amide), 147.2 (C-1), 139.7 (C=O tetrazine), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.6 & 129.3 (C-3 & C-5, C-H imidazole), 117.1 (C-4), 112.5 (C-2 & C-6), 48.8 (CH₂N-aniline), 46.6 (CH₂N-tetrazine); MS (ES): *m/z* 506.3 (M+H)⁺; ν_{max} (KBr) 3450m & 3150m (CONH₂), 1740s (C=O), 1675s (CONH₂), 1600m & 1510s (Ar-H) cm⁻¹. Anal. C₂₀H₁₉N₁₃O₄ · H₂O · 0.8AcOH, CHN.

3,3'-(2,2'-(4-Fuorophenylazanediyl))bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3c

Prepared according to General Method F. Imidazotetrazine **3c** was obtained as dark yellow solid (0.04 g, 42%): m.p. 290–291 °C; ¹H NMR (DMSO-d₆, 600 MHz) 8.78 (s, 2H, imidazole CH), 7.77 & 7.66 (2 × br s, 4H, 2 × CONH₂), 6.91 (m, 2H, 3-H & 5-H), 6.80 (m, 2H, 2-H & 6-H), 4.41 (t, *J* = 6.7 Hz, 4H, 2 × CH₂N-aniline), 3.76 (t, *J* = 6.7 Hz, 4H, 2 × CH₂N-tetrazine); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (C=O amide), 155.0 (d, ¹*J*_{CF} = 243 Hz, C-4), 144.1 (C-1), 139.7 (C=O tetrazine), 134.7 (Cq tetrazine), 131.3 (Cq imidazole), 129.3 (C-H imidazole), 116.0 (d, ²*J*_{CF} = 23.1 Hz, C-3 & C-5), 114.1 (d, ³*J*_{CF} = 7.2 Hz, C-2 & C-6), 49.4 (CH₂N-aniline), 46.5 (CH₂N-tetrazine); MS (ES): *m/z* 524.3 (M+H)⁺; 546.2 (M + Na)⁺; IR (KBr) 3450m (CONH₂), 1725s (C=O), 1675s (CONH₂), 1600m & 1510s (Ar-H) cm⁻¹. Anal. C₂₀H₁₈FN₁₃O₄ · 0.35 H₂O · 0.3 AcOH requires, CHN.

3,3'-(2,2'-(4-Methoxy-2-nitrophenylazanediyl))bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3f

Prepared according to General Method F. The product was purified by flash column chromatography (5% AcOH/CH₃CN) and imidazotetrazine **3f** was obtained as an orange/yellow

solid (0.21 g, 26%): m.p. 139–140 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.72 (s, 2H, imidazole CH), 7.77 & 7.67 (2 × br s, 4H, 2 × CONH₂), 7.49 (d, *J* = 9.2 Hz, 1H, 6-H), 7.16 (d, *J* = 3.0 Hz, 1H, 3-H), 7.04 (dd, *J* = 9.2, 3.0 Hz, 1H, 5-H), 4.32 (t, *J* = 6.2 Hz, 4H, 2 × CH₂N-aniline), 3.67 (s, 3H, OCH₃), 3.47 (t, *J* = 6.2 Hz, 4H, 2 × CH₂N-tetrazine); ¹³C NMR (DMSO-d₆, 151 MHz) 161.9 (C=O amide), 156.3 (C-4), 147.8 (C-2), 139.5 (C=O tetrazine), 135.6 (C-1), 134.8 (Cq tetrazine), 131.3 (Cq imidazole), 129.1 (C-H imidazole), 126.9 (C-5), 119.4 (C-6), 109.1 (C-3), 56.4 (CH₃O), 52.1 (CH₂N-aniline), 46.9 (CH₂N-tetrazine); MS (ES): *m/z* 581.3 (M+H)⁺⁺; 603.1 (M + Na)⁺⁺; IR (KBr) 3450m (CONH₂), 1750s (C=O), 1675s (CONH₂), 1600m & 1525s (Ar-H) cm⁻¹. Anal. C₂₁H₂₀N₁₄O₇·1.4 H₂O·0.4 AcOH, CHN.

3,3'-(2,2'-(4-Methoxyphenylazanediyl))bis(ethane-2,1-diyl))bis-(4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide) 3e

Prepared by a variation on General Method F using AcOH (0.17 M) in place of HCl. The product was purified by flash column chromatography (10% AcOH/CHCl₃) and **3e** was obtained as red solid (0.2 g, 11%): m.p. 178-179 °C. ¹H NMR (DMSO-d₆, 600 MHz) 8.75 (s, 2H, imidazole CH), 7.76 & 7.65 (2 × br s, 4H, 2 × CONH₂), 6.73 (d, *J* = 8.1 Hz, 2H, 3-H & 5-H), 6.62 (d, *J* = 8.1 Hz, 2H, 2-H & 6-H), 4.39 (t, *J* = 6.6 Hz, 4H, 2 × CH₂N-aniline), 3.72 (t, *J* = 6.6 Hz, 4H, 2 × CH₂N-tetrazine), 3.53(s, 3H, CH₃); ¹³C NMR (DMSO-d₆, 151 MHz) 162.0 (C=O amide), 152.0 (C-4), 141.5 (C-1), 139.6 (C=O tetrazine), 134.7 (Cq tetrazine), 131.2 (Cq imidazole), 129.2 (C-H imidazole), 115.2 & 114.9 (C-2 & C-6, C-3 & C-5), 55.6 (CH₃), 49.6 (CH₂N-aniline), 46.9 (CH₂N-tetrazine); MS (ES): *m/z* 536.3 (M+H)⁺⁺; 558.3 (M + Na)⁺⁺; IR (KBr) 3450m (CONH₂), 1750s (C=O), 1675s (CONH₂), 1600m & 1500s (Ar-H) cm⁻¹. Anal. C₂₁H₂₁N₁₃O₅, CHN.

***In vitro* Chemosensitivity**

Cells used were A2780 (human ovarian carcinoma, from European Collection of Cell Cultures), the MMR-deficient derivative A2780-Cp70 (gift of Professor G Margisson, University of Manchester, UK). Isogenic HCT116 p53^{+/+} and HCT116 p53^{-/-} came from Bert Vogelstein.³⁹ Cells

were plated into 96-well culture plates at 1×10^3 cells per well and incubated over night at 37 °C in a CO₂ enriched (5%) atmosphere to enable cells to adhere to the plate. Culture medium was removed and replaced with fresh medium containing test compound at concentrations ranging from 0 (controls) to 250 µM. Following 5 days incubation at 37 °C, cell survival was determined using the MTT assay. All TMZ-related compounds were dissolved in DMSO, and the final concentration of DMSO in the culture plates was <0.1% (v/v). PaTrin2 was used as an inhibitor of MGMT and cells were incubated with test compounds in the presence or absence of 10 µM PaTrin2

NCI Data Handling

Standard COMPARE and matrix COMPARE were run using the NCI database Data Build Date: 2012-04-28. GI₅₀ data were selected and where multiple datasets were available, those averaged from the larger number of individual experiments were used.

Supporting Information Available: including tabulated IC₅₀ data and statistical analysis for Figures 1 and 2; NCI mean graphs and COMPARE results for compounds **2d**, **3c–e**; HPLC analysis of new tetrazines **2**, **3**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Abbreviations Used. ATM, ataxia telangiectasia mutated serine/threonine protein kinase; ATR, ataxia telangiectasia and Rad3-related protein; BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea; CCNU, *N*-(2-chloroethyl)-*N'*-cyclohexyl-*N*-nitrosourea; CHB, chlorambucil; CP, cisplatin; DTIC, 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide; FANC, Fanconi's anemia; GBM, glioblastoma multiforme; MEL, melphalan; MGMT, *O*6-Methylguanine-DNA-methyltransferase; MMR, DNA Mismatch repair; 6MP, 6-mercaptopurine; MTIC, 5-(3-methyl-1-triazeno)imidazole-4-

carboxamide; MTZ, mitozolomide; QSAR, quantitative structure-activity relationship; 6TG, 6-thioguanione; TMZ, temozolomide.

*To whom correspondence should be addressed. Phone: +44 (0) 1274 234710.

Email: r.t.wheelhouse@brad.ac.uk.

§Present address: Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Sudan.

References

1. Sarkaria, J. N.; Kitange, G. J.; James, C. D.; Plummer, R.; Calvert, H.; Weller, M.; Wick, W. Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma. *Clin. Cancer Res.* **2008**, *14*, 2900–2908.
2. Zhang, J.; Stevens, M. F. G.; Bradshaw, T. D. Temozolomide: Mechanisms of Action, Repair and Resistance. *Curr. Mol. Pharmacol.* **2012**, *5*, 102–114.
3. Darkes, M. J. M.; Plosker, G. L.; Jarvis, B. Temozolomide a Review of its Use in the Treatment of Malignant Gliomas, Malignant Melanoma and Other Advanced Cancers *Am. J. Cancer* **2002**, *1*, 55–80
4. Stevens, M. F. G.; Hickman, J. A.; Langdon, S. P.; Chubb, D.; Vickers, L.; Stone, R.; Baig, G.; Goddard, C.; Gibson, N. W.; Slack, J. A.; Newton, C.; Lunt, E.; Fizames, C.; Lavelle, F. Antitumor Imidazotetrazines 13. Antitumor Activity and Pharmacokinetics in Mice of 8-

Carbamoyl-3-Methyl-Imidazo-[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045-M&B-39831), a Novel Drug with Potential as an Alternative to Dacarbazine. *Cancer Research* **1987**, 47, 5846–5852.

5. Shealy, Y. F.; Krauth, C. A. Imidazoles. II. 5(or 4)-(Monosubstituted triazeno)imidazole-4(or 5)-carboxamides. *J. Med. Chem.* **1966**, 9, 35–38.

6. Denny, B. J.; Wheelhouse, R. T.; Stevens, M. F. G.; Tsang, L. L. H. NMR and Molecular Modeling Investigation of the Mechanism of Activation of the Antitumor Drug Temozolomide and its Interaction with DNA. *Biochemistry* **1994**, 33, 9045–9051.

7. Wheelhouse, R. T.; Stevens, M. F. G. Decomposition of the Antitumour Drug Temozolomide in Deuteriated Phosphate Buffer: Methyl Group Transfer is Accompanied by Deuterium Exchange. *J. Chem. Soc., Chem. Commun.* **1993**, 1177–1179.

8. McGarrity, J. F.; Smyth, T. Hydrolysis of Diazomethane-Kinetics and Mechanism. *J. Am. Chem. Soc.* **1980**, 102, 7303–7308.

9. Svilar, D.; Dyavaiah, M.; Brown, A. R.; Tang, J.-b.; Li, J.; McDonald, P. R.; Shun, T. Y.; Braganza, A.; Wang, X.-h.; Maniar, S.; St Croix, C. M.; Lazo, J. S.; Pollack, I. F.; Begley, T. J.; Sobol, R. W. Alkylation Sensitivity Screens Reveal a Conserved Cross-species Functionome. *Mol. Cancer Res.* **2012**, 10, 1580–1596.

10. Schmidt, B. F.; Snyder, E. J.; Carroll, R. M.; Farnsworth, D. W.; Michejda, C. J.; Smith, R. H. Triazinines: Synthesis and Proteolytic Decomposition of a New Class of Cyclic Triazenes. *J. Org. Chem.* **1997**, 62, 8660–8665.

11. Schmiedekamp, A.; Smith, R. H.; Michejda, C. J. *Ab Initio* Studies of Triazenes in Relation to Experimental Findings. *J. Org. Chem.* **1988**, 53, 3433–3436.

12. Smith, R. H.; Wladkowski, B. D.; Taylor, J. E.; Thompson, E. J.; Pruski, B.; Klose, J. R.; Andrews, A. W.; Michejda, C. J. Acid-Catalyzed Decomposition of 1-Alkyltriazolines - a Mechanistic Study. *J. Org. Chem.* **1993**, 58, 2097–2103.

13. Wang, Y.; Wheelhouse, R. T.; Zhao, L.; Langnel, D. A. F.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 36. Conversion of 5-aminoimidazole-4-carboxamide to Imidazo-[5,1-d]-1,2,3,5-tetrazin4(3H)-ones and Imidazo-[1,5-a]-1,3,5-triazin4(3H)-ones Related in Structure to the Antitumour Agents Temozolomide and Mitozolomide. *J. Chem. Soc., Perkin Trans. I* **1998**, 1669–1676.
14. Arrowsmith, J.; Jennings, S. A.; Langnel, D. A. F.; Wheelhouse, R. T.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 39. Synthesis of Bis(imidazotetrazine)s with Saturated Spacer Groups. *J. Chem. Soc., Perkin Trans. I* **2000**, 4432–4438.
15. Garelnabi, E. A. E.; Pletsas, D.; Li, L.; Kiakos, K.; Karodia, N.; Hartley, J. A.; Phillips, R. M.; Wheelhouse, R. T. Strategy for Imidazotetrazines with Anticancer Activity Independent of MGMT and MMR. *ACS Med. Chem. Lett.* **2012**, 3, 965–968.
16. Pletsas, D.; Wheelhouse, R. T.; Pletsa, V.; Nicolaou, A.; Jenkins, T. C.; Bibby, M. C.; Kyrtopoulos, S. A. Polar, Functionalized Guanine-*O6* Derivatives Resistant to Repair by *O6*-Alkylguanine-DNA Alkyltransferase: Implications for the Design of DNA-modifying Drugs. *Eur. J. Med. Chem.* **2006**, 41, 330–339.
17. Arris, C. E.; Bleasdale, C.; Calvert, A. H.; Curtin, N. J.; Dalby, C.; Golding, B. T.; Griffin, R. J.; Lunn, J. M.; Major, G. N.; Newell, D. R. Probing the Active-Site and Mechanism of Action of *O6*-Methylguanine-DNA Methyltransferase With Substrate-Analogs (*O6*-Substituted Guanines). *Anti-Cancer Drug Design* **1994**, 9, 401–408.
18. Wheelhouse, R. T.; Wilman, D. E. V.; Thomson, W.; Stevens, M. F. G. Antitumour Imidazotetrazines. Part 31. The Synthesis of Isotopically Labelled Temozolomide and a Multinuclear (^1H , ^{13}C , ^{15}N) Magnetic Resonance Investigation of Temozolomide and Mitozolomide. *J. Chem. Soc., Perkin Trans. I* **1995**, 249–252.

19. Barvaux, V. A.; Ranson, M.; Brown, R.; McElhinney, R. S.; McMurry, T. B. H.; Margison, G. P. Dual Repair Modulation Reverses Temozolomide Resistance *in Vitro*. *Mol. Cancer Ther.* **2004**, *3*, 123–127.
20. McElhinney RS; Donnelly DJ; McCormick JE; Kelly J; Watson AJ; Rafferty JA; Elder RH; Middleton MR; Willington MA; McMurry TB; GP, M. Novel O6-(Hetaryl methyl)guanines Having Basic Rings in the Side Chain. *J. Med. Chem.* **1998**, *41*, 5265–5271.
21. Judson, P. L.; Blair Harkness, C.; Boente, M. P.; Downs, L. S., Jr.; Argenta, P. A.; Carson, L. F. A Phase II Evaluation of Temozolomide in Patients with Recurrent Epithelial Ovarian Cancer. *Gynecol. Oncol.* **2004**, *93*, 667–670.
22. Boyd, M. R.; Pauli, K. D. Some Practical Considerations and Applications of the National-Cancer-Institute *in-Vitro* Anticancer Drug Discovery Screen. *Drug Development Res.* **1995**, *34*, 91–109.
23. Leteurtre, F.; Kohlhagen, G.; Paull, K. D.; Pommier, Y. Topoisomerase II Inhibition and Cytotoxicity of the Anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute Preclinical Antitumor Drug Discovery. *J. Nat. Cancer Inst.* **1994**, *86*, 1239–1244.
24. Karran, P.; Attard, N. Thiopurines in Current Medical Practice: Molecular Mechanisms and Contributions to Therapy-related Cancer. *Nature Rev. Cancer* **2008**, *8*, 24–36.
25. Karran, P. Thiopurines, DNA Damage, DNA Repair and Therapy-related Cancer. *British Medical Bull.* **2006**, *79–80*, 153–170.
26. Genecards (The Human Genome Compendium) <http://www.genecards.org>, Accessed March 7th 2013.
27. Nishizuka, S.; Charboneau, L.; Young, L.; Major, S.; Reinhold, W. C.; Waltham, M.; Kouros-Mehr, H.; Bussey, K. J.; Lee, J. K.; Espina, V. Proteomic Profiling of the NCI-60 Cancer Cell Lines Using New High-density Reverse-phase Lysate Microarrays. *Proc. Nat. Acad. Sci. USA* **2003**, *100*, 14229–14234.

28. Hirose, Y.; Katayama, M.; Stokoe, D.; Haas-Kogan, D. A.; Berger, M. S.; Pieper, R. O. The p38 Mitogen-Activated Protein Kinase Pathway Links the DNA Mismatch Repair System to the G2 Checkpoint and to Resistance to Chemotherapeutic DNA-Methylating Agents. *Mol. Cell. Biol.* **2003**, 8306–8315.
29. Zhang, J.; Stevens, M. F. G.; Hummersone, M.; Madhusudan, S.; Laughton, C. A.; Bradshaw, T. D. Certain Imidazotetrazines Escape O6-Methylguanine-DNA Methyltransferase and Mismatch Repair. *Oncology* **2011**, 80, 195–207.
30. Liu, L.; Taverna, P.; Whitacre, C. M.; Chatterjee, S.; Gerson, S. L. Pharmacologic Disruption of Base Excision Repair Sensitizes Mismatch Repair-deficient and -proficient Colon Cancer Cells to Methylating Agents. *Clin. Cancer Res.* **1999**, 5, 2908–2917.
31. Dinca, E. B.; Lu, K. V.; Sarkaria, J. N.; Pieper, R. O.; Prados, M. D.; Haas-Kogan, D. A.; VandenBerg, S. R.; Berger, M. S.; James, C. D. p53 Small-molecule Inhibitor Enhances Temozolomide Cytotoxic Activity against Intracranial Glioblastoma Xenografts. *Cancer Res.* **2008**, 10034–10039.
32. Mladek, A. C.; Ramirez, Y.; Pletsas, D.; Wheelhouse, R. T.; Phillips, R. M.; Ross, A. H.; Knudson, K.; Sarkaria, J. N. Cytotoxicity of a Novel Bi-functional Temozolomide Analog, DP68, is Independent of MGMT Status in Glioblastoma Models. *Proc. American Assoc. Cancer Res.* **2013**, abstract 4476.
33. Boberg, F. über 1.2-Dithia-cyclopentene, IX Alkalische Spaltung des 1.2-Dithia-cyclopentenon-(3)-Rings. *Leibigs* **1965**, 683, 132–148.
34. Honnalli, S. S.; Ronad, P. M.; Vijaybhasker, K.; Hukkeri, V. I.; Kumar, R. Synthesis and Antimicrobial Activity of Some 2,5-Disubstituted 1,3,4-Oxadiazoles. *Heterocyclic Commun.* **2005**, 11, 505–508.
35. Siddiqui, A. A.; Arora, A.; Siddiqui, N.; Misra, A. Synthesis of Some 1,2,4-Triazoles as Potential Antifungal Agents. *Indian J. Chem. B* **2005**, 44, 838–841.

36. De, K.; Legros, J.; Crousse, B.; Bonnet-Delpon, D. Solvent-Promoted and -Controlled Aza-Michael Reaction with Aromatic Amines. *J. Org. Chem.* **2009**, *74*, 6260–6265.
37. Damera, K.; Reddy, K. L.; Sharma, G. V. M. An Efficient ZrCl₄ Catalyzed Aza-Michael Addition Reaction: Synthesis of C-Linked Carbo beta(3)-Amino Acids. *Lett. Org. Chem.* **2009**, *6*, 151–155.
38. Kotera, M. Luminescence of Hydrazide Derivatives Containing Rare Earth Elements *Nippon Kagaku Kaishi* **1979**, 1279–1281.
39. Bunz, F.; Dutriaux, A.; Lengauer, C.; Waldman, T.; Zhou, S.; Brown, J. P.; Sedivy, J. M.; Kinzler, K. W.; Vogelstein, B. Requirement for p53 and p21 to Sustain G-2 Arrest After DNA Damage. *Science* **1998**, 1497–1500.

TOC Graphic

Synthesis and Quantitative Structure–Activity Relationship of
Imidazotetrazine Prodrugs with Activity Independent of O6-
Methylguanine-DNA-methyltransferase, DNA Mismatch Repair and p53.

Dimitrios Pletsas,[†] Elrashied A.E. Garelnabi,[†] Li Li,[‡] Roger M. Phillips,[‡]

Richard T. Wheelhouse^{†}*

[†]School of Pharmacy and [‡]Institute of Cancer Therapeutics,

University of Bradford, BRADFORD, BD7 1DP, UK.

Supporting Information

Page	
S2	Tables S1 and S2. IC ₅₀ Data for Figures 1 and 2.
S6	Table S3 Statistical Analysis of Chemosensitivity Data.
S7	Table S4. Listing and Coding of NCI Cell Lines used in the figures.
	Table S5. NSC Codes for 2d , 3c-e .
S9	Figure S1. NCI Mean Graphs for TMZ.
S10	Figure S2. NCI Mean Graphs for 2d .
S11	Figure S3. NCI Mean Graphs for 3c .
S12	Figure S4. NCI Mean Graphs for 3d .
S13	Figure S5. NCI Mean Graphs for 3e .
S14	Figure S6. Superimposed mean graphs of 2d , 3c-e , MTZ and CP.
S15	Table S6. COMPARE Results for 2d .
S16	Table S7. COMPARE Results for 3c .
S17	Table S8. COMPARE Results for 3d .
S18	Table S9. COMPARE Results for 3e .
S20	Figure S6. Plot of logGI ₅₀ vs MGMT.
S21	Figure S7. Plot of logGI ₅₀ vs hMLH1
S22	Figure S8. Plot of logGI ₅₀ vs MSH6.
S23	HPLC Analysis of New Imidazotetrazines.
S25	Elemental Analysis Data for New Imidazotetrazines.
S26–40	Highfield ¹ H NMR Spectra of New Imidazotetrazines.

ID			IC ₅₀ / μM								IC ₅₀ Ratios			
ID	Structures	σ	A2780 (MMR ⁺) / μM				A2780-Cp70 (MMR ⁺) / μM				Cp70 / A2780		- / + PaTrin-2	
			- PaTrin-2	+ PaTrin-2	- PaTrin-2	+ PaTrin-2	- PaTrin-2 + PaTrin-2	A2780	Cp70					
TMZ			Mean	Stdev	Mean	Stdev	Mean	Stdev	Mean	Stdev				
MTZ			>257		8.6	0.32	>257		>231		>1.1	>27	>30	
MEL			95	5.0	15	1.1	>100		51	2.7	3.5	6.5	>2.0	
CisPt			16.84	1.47	14.5	5.59	36.05	6.08	15.99	3.07	8.7			
			23.87	3.88	11.83	3.34	40.95	3.28	32.24	6.13				
Crosslinkers														
3a		0	1.4	0.40	2.4	0.02	9.5	4.7	12	2.0	7.0	5.0	0.56	0.79
3b		-0.170	0.70	0.23	1.3	0.07	6.5	1.0	7.0	0.10	9.3	5.8	0.56	0.89
3c		0.062	15	7.7	2.6	0.49	11	2.3	15	0.50	0.7	5.7	5.9	0.75
3d		0.227	12	0.01	4.7	0.64	31	3.5	26	2.0	2.6	5.6	2.6	1.2

Crosslinkers

3e	-0.268	1.4	0.36	2.08	0.03	11	1.5	11	0.85	8.3	5.4	0.66	1.0
3h		36	20			46	12			1.3			

Table S1 *In vitro* Chemosensitivity Data for Bifunctional Imidazotetrazines **3**

ID	Structures	σ	IC ₅₀ / μ M						IC ₅₀ Ratios					
			A2780 (MMR ⁺) / μ M		A2780-Cp70 (MMR ⁻) / μ M		Cp70 / A2780		- / + PaTrin-2					
			- PaTrin-2 Mean	+ PaTrin-2 Stdev	- PaTrin-2 Mean	+ PaTrin-2 Stdev	- PaTrin-2 Mean	+ PaTrin-2 Stdev	- PaTrin-2	+ PaTrin-2	A2780	Cp70		
2a		0	68	9.29	41	0.57	79	15	> 110	1.2	> 2.7	1.7	<0.72	
2b		-0.170	54	11	34	3.1	62	10	94	3.3	1.2	2.8	1.6	0.66
2c		0.05	73.25	10.22	43.98	9.64	21.54	2.8			0.29	1.8		
2d		0.227	23	2.1	22	3.5	83	7.9	67	1.2	3.7	3.1	1.1	1.2
2f		0.77	31.63	2.76	10.52	2.51	72.69	12.04	20.87	2.86	2.3	2.0	3.0	3.5

2g		19	3.1	8.6	0.32	50	8.7	83	24	2.7	9.7	2.2	0.61
2h		113	31			137	26			1.2			
2j		51	6.7			203	24			4.0			
2k		42	17			148	2			3.5			

Table S2 *In vitro* Chemosensitivity Data for Monofunctional Imidazotetrazines **2**

Compound	P values for Group 1 ^a	P values for Group 2 ^a
TMZ	<0.01	<0.01
MTZ	<0.01	<0.01
MEL	>0.05	>0.05
CP	<0.01	<0.01
3a	>0.05	<0.01
3b	>0.05	<0.01
3c	<0.01	<0.01
3d	<0.01	<0.01
3e	>0.05	<0.01
3f	n/a	n/a
2a	<0.01	<0.01
2b	<0.01	<0.01
2c	<0.01	n/a*
2d	>0.05	<0.01
2e	<0.01	<0.05
2f	n/a	n/a
2g	<0.01	<0.01
2h	n/a	n/a
2i	n/a	n/a

Table S3. Statistical Analysis of Chemosensitivity Data

^a Student t-test analysis of chemosensitivity data for Group 1 (A2780 vs A2780 + Patrin2) and Group 2 (A2780 + Patrin2 vs A2780 Cp70 + Patrin 2). Statistically significant differences were defined when $P < 0.05$; n/a denotes not available due to incomplete data sets or, in the case of n/a*, the absence of triplicate experiments ($n = 1$).

Number	Sub-panel Name	Cell Name	Number	Sub-panel Name	Cell Name
1	Leukemia	CCRF-CEM	31	Melanoma	M14
2	Leukemia	HL-60(TB)	32	Melanoma	SK-MEL-2
3	Leukemia	K-562	33	Melanoma	SK-MEL-28
4	Leukemia	MOLT-4	34	Melanoma	SK-MEL-5
5	Leukemia	RPMI-8226	35	Melanoma	UACC-257
6	Leukemia	SR	36	Melanoma	UACC-62
7	Non-Small Cell Lung Cancer	A549/ATCC	37	Ovarian Cancer	IGROV1
8	Non-Small Cell Lung Cancer	EKVX	38	Ovarian Cancer	OVCAR-3
9	Non-Small Cell Lung Cancer	HOP-62	39	Ovarian Cancer	OVCAR-4
10	Non-Small Cell Lung Cancer	HOP-92	40	Ovarian Cancer	OVCAR-5
11	Non-Small Cell Lung Cancer	NCI-H226	41	Ovarian Cancer	OVCAR-8
12	Non-Small Cell Lung Cancer	NCI-H23	42	Ovarian Cancer	SK-OV-3
13	Non-Small Cell Lung Cancer	NCI-H322M	43	Renal Cancer	786-0
14	Non-Small Cell Lung Cancer	NCI-H460	44	Renal Cancer	A498
15	Cancer	NCI-H522	45	Renal Cancer	ACHN
16	Colon Cancer	COLO 205	46	Renal Cancer	CAKI-1
18	Colon Cancer	HCT-116	47	Renal Cancer	RXF 393
19	Colon Cancer	HCT-15	48	Renal Cancer	SN12C
20	Colon Cancer	HT29	49	Renal Cancer	TK-10
21	Colon Cancer	KM12	50	Renal Cancer	UO-31
22	Colon Cancer	SW-620	51	Prostate Cancer	PC-3
23	CNS Cancer	SF-268	52	Prostate Cancer	DU-145
24	CNS Cancer	SF-295	53	Breast Cancer	MCF7
25	CNS Cancer	SF-539	54	Breast Cancer	NCI/ADR-RES
26	CNS Cancer	SNB-19	55	Breast Cancer	MDA-MB-231/ATCC
27	CNS Cancer	SNB-75	56	Breast Cancer	HS 578T
28	CNS Cancer	U251	57	Breast Cancer	MDA-MB-435
29	Melanoma	LOX IMVI	59	Breast Cancer	BT-549
30	Melanoma	MALME-3M	60	Breast Cancer	T-47D
			61	Breast Cancer	MDA-MB-468

Table S4. Listing of the NCI60 cell lines assigned arbitrary numbers in Figures 4 and S2-5

Compound Number	NCI Code
2d	NSC746818
3c	NSC746815
3d	NSC746816
3e	NSC746817
TMZ	NSC362856

Table S5. NCI Code Numbers for compounds **2d**, **3c-e**.

Figures S1-6

NCI Mean graphs for TMZ, and compounds **2d**, **3c-e**.

Developmental Therapeutics Program Mean Graph
Selected Data Vectors

NSC:S362856 Endpt:LC50 ExpId:AVGDATA hiConc:-4.0
TEMOZOLOMIDE (USAN)
vectorId: 121552
count expts: 2
count cell lines: 67
std dev: 0.0

NSC:S362856 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0
TEMOZOLOMIDE (USAN)
vectorId: 135005
count expts: 2
count cell lines: 67
std dev: 0.066

NSC:S362856 Endpt:TGI ExpId:AVGDATA hiConc:-4.0
TEMOZOLOMIDE (USAN)
vectorId: 351954
count expts: 2
count cell lines: 67
std dev: 0.0

Small Cell Lung			
DMS114	-4.00	-4.00	-4.00
Leukemia			
CCRF-CEM	-4.00	-4.11	-4.00
HL-60(TB)	-4.00	-4.07	-4.00
K-562	-4.00	-4.12	-4.00
MOLT-4	-4.00	-4.08	-4.00
RPMI-8226	-4.00	-4.00	-4.00
SR	-4.00	-4.00	-4.00
Non-SmallCellLung			
A549/ATCC	-4.00	-4.00	-4.00
EKVX	-4.00	-4.00	-4.00
HOP-18	-4.00	-4.00	-4.00
HOP-62	-4.00	-4.00	-4.00
HOP-92	-4.00	-4.00	-4.00
NCI-H226	-4.00	-4.00	-4.00
NCI-H23	-4.00	-4.00	-4.00
NCI-H322M	-4.00	-4.00	-4.00
NCI-H460	-4.00	-4.00	-4.00
NCI-H522	-4.00	-4.00	-4.00
LXFL529	-4.00	-4.00	-4.00
Colon			
COLO205	-4.00	-4.00	-4.00
DLD-1	-4.00	-4.00	-4.00
HCC-2998	-4.00	-4.00	-4.00
HCT-116	-4.00	-4.00	-4.00
HCT-15	-4.00	-4.00	-4.00
HT29	-4.00	-4.00	-4.00
KM12	-4.00	-4.00	-4.00
KM20L2	-4.00	-4.00	-4.00
SW-620	-4.00	-4.00	-4.00
CNS			
SF-268	-4.00	-4.00	-4.00
SF-295	-4.00	-4.00	-4.00
SF-539	-4.00	-4.00	-4.00
SNB-19	-4.00	-4.00	-4.00
SNB-75	-4.00	-4.15	-4.00
SNB-78	-4.00	-4.00	-4.00
U251	-4.00	-4.00	-4.00
XF498	-4.00	-4.00	-4.00
Melanoma			
LOXIMV1	-4.00	-4.09	-4.00
MALME-3M	-4.00	-4.00	-4.00
M14	-4.00	-4.00	-4.00
MDA-MB-435	-4.00	-4.00	-4.00
M19-MEL	-4.00	-4.00	-4.00
SK-MEL-2	-4.00	-4.00	-4.00
SK-MEL-28	-4.00	-4.00	-4.00
SK-MEL-5	-4.00	-4.00	-4.00
UACC-257	-4.00	-4.00	-4.00
UACC-62	-4.00	-4.00	-4.00
Ovarian			
IGROV1	-4.00	-4.00	-4.00
OVCAR-3	-4.00	-4.00	-4.00
OVCAR-4	-4.00	-4.00	-4.00
OVCAR-5	-4.00	-4.00	-4.00
OVCAR-8	-4.00	-4.00	-4.00
NCI/ADR-RES	-4.00	-4.00	-4.00
SK-OV-3	-4.00	-4.23	-4.00
Renal			
786-0	-4.00	-4.00	-4.00
ACHN	-4.00	-4.00	-4.00
CAKI-1	-4.00	-4.00	-4.00
RXF393	-4.00	-4.00	-4.00
SN12C	-4.00	-4.00	-4.00
TK-10	-4.00	-4.00	-4.00
UO-31	-4.00	-4.13	-4.00
Prostate			
PC-3	-4.00	-4.00	-4.00
DU-145	-4.00	-4.00	-4.00
Breast			
MCF7	-4.00	-4.00	-4.00
MDA-MB-231/ATCC	-4.00	-4.00	-4.00
HS578T	-4.00	-4.00	-4.00
MDA-N	-4.00	-4.00	-4.00
BT-549	-4.00	-4.00	-4.00
T-47D	-4.00	-4.00	-4.00
summary			
MG_MID	-4.00	-4.01	-4.00
Delta	0.00	0.01	0.00
Range	0.00	0.23	0.00

Developmental Therapeutics Program Mean Graph
Selected Data Vectors

NSC:S746818 Endpt:LC50 ExpId:AVGDATA hiConc:-4.0

vectorId: 143081
count expts: 1
count cell lines: 59
std dev: 0.0050

NSC:S746818 Endpt:GI50 ExpId:AVGDATA hiConc:-4.0

vectorId: 237623
count expts: 1
count cell lines: 59
std dev: 0.579

NSC:S746818 Endpt:TGI ExpId:AVGDATA hiConc:-4.0

vectorId: 355078
count expts: 1
count cell lines: 59
std dev: 0.107

Leukemia

CCRF-CEM
HL-60(TB)
K-562
MOLT-4
RPMI-8226
SR

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-5.90
-5.34
-5.37
-5.59
-6.04
-4.68

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

Non-SmallCell lung

A549/ATCC
EKVX
HOP-62
HOP-92
NCI-H226
NCI-H23
NCI-H322M
NCI-H460
NCI-H522

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-4.00
-4.12
-6.05
-5.12
-4.18
-4.10
-4.05
-4.38
-4.65

-4.00
-4.00
-4.40
-4.00
-4.00
-4.00
-4.00
-4.00
-4.03

Colon

COLO205
HCT-116
HCT-15
HT29
KM12
SW-620

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-4.55
-4.63
-4.23
-4.17
-4.00
-4.74

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

CNS

SF-268
SF-295
SF-539
SNB-19
SNB-75
U251

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-4.48
-5.17
-4.74
-4.00
-5.19
-4.17

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

Melanoma

LOXIMVI
MALME-3M
M14
MDA-MB-435
SK-MEL-2
SK-MEL-28
SK-MEL-5
UACC-257
UACC-62

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-5.54
-4.00
-5.37
-4.56
-4.00
-4.00
-4.52
-4.00
-4.87

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

Ovarian

IGROV1
OVCAR-3
OVCAR-4
OVCAR-5
OVCAR-8
NCI/ADR-RES
SK-OV-3

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-4.48
-4.58
-5.43
-4.21
-5.06
-4.49
-5.60

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00
-4.44

Renal

786-0
A498
ACHN
CAKI-1
RXF393
SN12C
TK-10
UO-31

-4.00
-4.00
-4.00
-4.00
-4.04
-4.00
-4.00
-4.00

-5.31
-4.19
-4.53
-4.45
-4.70
-4.28
-5.35
-5.21

-4.45
-4.00
-4.00
-4.00
-4.37
-4.00
-4.00
-4.00

Prostate

PC-3

-4.00

-4.34

-4.00

Breast

MCF7
MDA-MB-231/ATCC
HS578T
BT-549
T-47D
MDA-MB-468

-4.00
-4.00
-4.00
-4.00
-4.00
-4.00

-4.31
-5.06
-4.00
-4.10
-4.56
-5.34

-4.00
-4.00
-4.00
-4.00
-4.00
-4.19

summary

MG_MID
Delta
Range

-4.00
0.00
0.04

-4.69
0.69
2.05

-4.03
0.03
0.45

Developmental Therapeutics Program Mean Graph
Selected Data Vectors

NSC:S746815 Endpt:L:C50 ExpId:AVGDATA hiConc:-4.5

vectorId: 175223
count expts: 2
count cell lines: 60
std dev: 0.0

NSC:S746815 Endpt:TGI ExpId:AVGDATA hiConc:-4.5

vectorId: 291496
count expts: 2
count cell lines: 60
std dev: 0.133

NSC:S746815 Endpt:GI50 ExpId:AVGDATA hiConc:-4.5

vectorId: 409266
count expts: 2
count cell lines: 60
std dev: 0.691

Leukemia

Non-SmallCell lung

Colon

CNS

Melanoma

Ovarian

Renal

Prostate

Breast

summary

Developmental Therapeutics Program Mean Graph
Selected Data Vectors

NSC:S746816 Endpt:LC50 ExpId:AVGDATA hiConc:-4.5

NSC:S746816 Endpt:TGI ExpId:AVGDATA hiConc:-4.5

NSC:S746816 Endpt:GI50 ExpId:AVGDATA hiConc:-4.5

vectorId: 62154
count expts: 2
count cell lines: 60
std dev: 0.0

vectorId: 410880
count expts: 2
count cell lines: 60
std dev: 0.076

vectorId: 413058
count expts: 2
count cell lines: 60
std dev: 0.515

Leukemia

Non-SmallCell lung

Colon

CNS

Melanoma

Ovarian

Renal

Prostate

Breast

summary

Developmental Therapeutics Program Mean Graph
Selected Data Vectors

NSC:S746817 Endpt:LC50 ExpId:AVGDATA hiConc:-4.5

vectorId: 81943
count expts: 1
count cell lines: 59
std dev: 0.0

NSC:S746817 Endpt:TGI ExpId:AVGDATA hiConc:-4.5

vectorId: 399233
count expts: 1
count cell lines: 59
std dev: 0.026

NSC:S746817 Endpt:GI50 ExpId:AVGDATA hiConc:-4.5

vectorId: 410257
count expts: 1
count cell lines: 59
std dev: 0.461

Leukemia

CCRF-CEM	-4.49	-4.49	-6.04	
HL-60(TB)	-4.49	-4.49	-5.81	
K-562	-4.49	-4.49	-5.20	
MOLT-4	-4.49	-4.49	-5.81	
RPMI-8226	-4.49	-4.49	-6.29	
SR	-4.49	-4.49	-5.69	

Non-SmallCellLung

A549/ATCC	-4.49	-4.49	-4.49	
ECVX	-4.49	-4.49	-4.49	
HOP-62	-4.49	-4.49	-4.49	
HOP-92	-4.49	-4.49	-4.83	
NCI-H226	-4.49	-4.49	-4.49	
NCI-H23	-4.49	-4.49	-4.54	
NCI-H322M	-4.49	-4.49	-4.49	
NCI-H460	-4.49	-4.49	-4.49	
NCI-H522	-4.49	-4.49	-5.15	

Colon

COLO205	-4.49	-4.49	-4.49	
HCT-116	-4.49	-4.49	-4.72	
HCT-15	-4.49	-4.49	-4.49	
HT29	-4.49	-4.49	-4.49	
KM12	-4.49	-4.49	-4.49	
SW-620	-4.49	-4.49	-4.86	

CNS

SF-268	-4.49	-4.49	-4.49	
SF-295	-4.49	-4.49	-5.09	
SF-539	-4.49	-4.49	-4.92	
SNB-19	-4.49	-4.49	-4.49	
SNB-75	-4.49	-4.49	-4.82	
U251	-4.49	-4.49	-4.49	

Melanoma

LOXIMVI	-4.49	-4.49	-5.74	
MALME-3M	-4.49	-4.49	-4.49	
M14	-4.49	-4.49	-5.20	
MDA-MB-435	-4.49	-4.49	-4.58	
SK-MEL-2	-4.49	-4.49	-4.49	
SK-MEL-28	-4.49	-4.49	-4.49	
SK-MEL-5	-4.49	-4.49	-4.49	
UACC-257	-4.49	-4.49	-4.49	
UACC-62	-4.49	-4.49	-4.82	

Ovarian

IGROV1	-4.49	-4.49	-4.52	
OVCAR-3	-4.49	-4.49	-4.49	
OVCAR-4	-4.49	-4.49	-5.28	
OVCAR-5	-4.49	-4.49	-4.49	
OVCAR-8	-4.49	-4.49	-4.68	
NCI/ADR-RES	-4.49	-4.49	-4.64	
SK-OV-3	-4.49	-4.49	-5.67	

Renal

786-0	-4.49	-4.49	-4.75	
A498	-4.49	-4.49	-4.49	
ACHN	-4.49	-4.49	-5.01	
CAKI-1	-4.49	-4.49	-4.82	
RXF393	-4.49	-4.49	-4.49	
SN12C	-4.49	-4.49	-4.78	
TK-10	-4.49	-4.49	-5.26	
UO-31	-4.49	-4.49	-4.97	

Prostate

PC-3	-4.49	-4.49	-4.49	
DU-145	-4.49	-4.49	-4.63	

Breast

MCF7	-4.49	-4.49	-4.85	
MDA-MB-231/ATCC	-4.49	-4.49	-4.54	
HS578T	-4.49	-4.49	-4.49	
BT-549	-4.49	-4.49	-4.49	
T-47D	-4.49	-4.49	-4.80	
MDA-MB-468	-4.49	-4.69	-5.43	

summary

MG_MID	-4.49	-4.49	-4.83	
Delta	0.00	0.00	0.35	
Range	0.00	0.20	1.80

Table S6. COMPARE Results for 2d using GI₅₀ as seed in the Standard Agents Database

Rank	P	Target Vector Identity for Display	Target Vector
1	0.669	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	DTIC
2	0.615	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	DTIC
3	0.571	NSC:S755 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	6-mercaptopurine
4	0.566	NSC:S71851 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	A-TGDR
5	0.563	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	thioguanine
6	0.556	NSC:S71261 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	B-TGDR
7	0.476	NSC:S406021 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	ARA-6-MP
8	0.467	NSC:S293015 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	flavoneacetic acid ester
9	0.453	NSC:S320846 Endpt:GI50 Expld:AVGDATA hiConc:-3.9	batracylin
10	0.438	NSC:S284751 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	8Cl-cyc-AMP
11	0.431	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	melfalan
12	0.425	NSC:S314055 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	SR2555 (nitroimidazole)
13	0.422	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	mitozolamide
14	0.414	NSC:S1895 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	guanazole
15	0.404	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	chlorambucil
16	0.4	NSC:S3051 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	R-methylformamide
17	0.393	NSC:S286193 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	tiazofurin
18	0.387	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	thioguanine
19	0.374	NSC:S375575 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	cyclopentenylcytosine
20	0.368	NSC:S261726 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	3-deazaguanine
21	0.361	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	mitozolamide
22	0.357	NSC:S95678 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	3HP
23	0.356	NSC:S344007 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazine alkylator
24	0.354	NSC:S321803 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	nitroestrone
25	0.349	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	melfalan
26	0.344	NSC:S109724 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	iphosphamide
27	0.343	NSC:S226080 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	rapamycin
28	0.342	NSC:S253272 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	caracemide
29	0.342	NSC:S73754 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	fluorodopan
30	0.34	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	dianhydrogalatitol
31	0.333	NSC:S32946 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	methyl-GAG
32	0.332	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	chlorambucil
33	0.331	NSC:S133100 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	rifamycin SV
34	0.33	NSC:S286193 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	tiazofurin
35	0.325	NSC:S192965 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	spirogermanium
36	0.324	NSC:S366140 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	pyrazoloacridine
37	0.324	NSC:S344007 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	piperazine alkylator
38	0.32	NSC:S172112 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	spirohydantoin mustard
39	0.319	NSC:S375575 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	cyclopentenylcytosine
40	0.318	NSC:S602668 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	carmethizole
41	0.316	NSC:S167780 Endpt:GI50 Expld:AVGDATA hiConc:-3.9	asaley
42	0.316	NSC:S338720 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	penclomedine
43	0.315	NSC:S338947 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	clomesone
44	0.314	NSC:S34462 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	uracil nitrogen mustard
45	0.311	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	m-AMSA (amsacrine)
46	0.31	NSC:S77037 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	D-tetrandrine
47	0.31	NSC:S150014 Endpt:GI50 Expld:AVGDATA hiConc:-2.5	hydrazine sulfate
48	0.309	NSC:S139490 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	emofolin sodium
49	0.308	NSC:S135758 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazinedione
50	0.307	NSC:S107392 Endpt:GI50 Expld:AVGDATA hiConc:-2.8	5HP
1	-0.237	NSC:S3053 Endpt:GI50 Expld:AVGDATA hiConc:-10.0	actinomycin D

Table S7. COMPARE Results for 3c using GI₅₀ as seed in the Standard Agents Database

Rank	P	Target Vector Identity for Display	Target Vector
1	0.751	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	DTIC
2	0.723	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	DTIC
3	0.56	NSC:S71851 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	A-TGDR
4	0.543	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	thioguanine
5	0.524	NSC:S755 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	6-mercaptapurine
6	0.477	NSC:S71261 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	B-TGDR
7	0.466	NSC:S406021 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	ARA-6-MP
8	0.457	NSC:S293015 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	flavoneacetic acid ester
9	0.433	NSC:S153858 Endpt:GI50 Expld:AVGDATA hiConc:-8.6	maytansine
10	0.42	NSC:S192965 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	spirogermanium
11	0.412	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	chlorambucil
12	0.409	NSC:S261726 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	3-deazaguanine
13	0.406	NSC:S253272 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	caracemide
14	0.402	NSC:S375575 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	cyclopentenylcytosine
15	0.399	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	melphalan
16	0.399	NSC:S77037 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	D-tetrandrine
17	0.395	NSC:S284751 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	8Cl-cyc-AMP
18	0.394	NSC:S73754 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	fluorodopan
19	0.374	NSC:S141537 Endpt:GI50 Expld:AVGDATA hiConc:-7.0	anguidine
20	0.369	NSC:S303861 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	L-cysteine analogue
21	0.366	NSC:S344007 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazine alkylator
22	0.364	NSC:S409962 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	BCNU
23	0.358	NSC:S73754 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	fluorodopan
24	0.351	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	m-AMSA (amsacrine)
25	0.347	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	mitozolamide
26	0.346	NSC:S102627 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	Yoshi-864
27	0.346	NSC:S320846 Endpt:GI50 Expld:AVGDATA hiConc:-3.9	batracylin
28	0.342	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	mitozolamide
29	0.341	NSC:S95441 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	methyl-CCNU
30	0.341	NSC:S1895 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	guanazole
31	0.339	NSC:S291643 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	pyrimidine-5-glycidialdehyde
32	0.338	NSC:S361456 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	pyrazine diazohydroxide
33	0.336	NSC:S95441 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	methyl-CCNU
34	0.335	NSC:S126771 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	dichloroallyl lawsone
35	0.333	NSC:S133100 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	rifamycin SV
36	0.332	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	melphalan
37	0.33	NSC:S139490 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	emofolin sodium
38	0.327	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	chlorambucil
39	0.325	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	dianhydrogalatitol
40	0.321	NSC:S119875 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	cisplatin
41	0.319	NSC:S6396 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	thio-tepa
42	0.318	NSC:S348948 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	cyclodisone
43	0.316	NSC:S409962 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	BCNU
44	0.313	NSC:S82151 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	daunorubicin (daunomycin)
45	0.312	NSC:S150014 Endpt:GI50 Expld:AVGDATA hiConc:-2.5	hydrazine sulfate
46	0.312	NSC:S32946 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	methyl-GAG
47	0.311	NSC:S126849 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	3-deazauridine
48	0.31	NSC:S286193 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	tiazofurin
49	0.309	NSC:S34462 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	uracil nitrogen mustard
50	0.304	NSC:S269148 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	menogaril
1	-0.261	NSC:S357704 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	cyanomorpholino-ADR
2	-0.233	NSC:S24559 Endpt:GI50 Expld:AVGDATA hiConc:-9.0	mitramycin
3	-0.213	NSC:S118742 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	pentamethylmelamine
4	-0.209	NSC:S283162 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	trimethyltrimethylolmelamine

Table S8. COMPARE Results for **3d** using GI₅₀ as seed in the Standard Agents Database

Rank	P	Target Vector Identity for Display	Target Vector
1	0.717	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	DTIC
2	0.638	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	DTIC
3	0.539	NSC:S755 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	6-mercaptopurine
4	0.512	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	thioguanine
5	0.504	NSC:S71851 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	A-TGDR
6	0.469	NSC:S71261 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	B-TGDR
7	0.396	NSC:S261726 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	3-deazaguanine
8	0.392	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	mitozolamide
9	0.38	NSC:S142982 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	hycanthone
10	0.377	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	mitozolamide
11	0.373	NSC:S192965 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	spirogermanium
12	0.362	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	melphalan
13	0.362	NSC:S320846 Endpt:GI50 Expld:AVGDATA hiConc:-3.9	batracylin
14	0.359	NSC:S293015 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	flavoneacetic acid ester
15	0.358	NSC:S344007 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazine alkylator
16	0.352	NSC:S119875 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	cisplatin
17	0.347	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	dianhydrogalatitol
18	0.338	NSC:S406021 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	ARA-6-MP
19	0.331	NSC:S153858 Endpt:GI50 Expld:AVGDATA hiConc:-8.6	maytansine
20	0.329	NSC:S119875 Endpt:GI50 Expld:AVGDATA hiConc:-4.3	cisplatin
21	0.329	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	chlorambucil
22	0.324	NSC:S409962 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	BCNU
23	0.319	NSC:S284751 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	8Cl-cyc-AMP
24	0.316	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	melphalan
25	0.316	NSC:S375575 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	cyclopentenylcytosine
26	0.314	NSC:S178248 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	chlorozotocin
27	0.309	NSC:S141537 Endpt:GI50 Expld:AVGDATA hiConc:-7.0	anguidine
28	0.307	NSC:S1895 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	guanazole
29	0.306	NSC:S82151 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	daunorubicin (daunomycin)
30	0.305	NSC:S102627 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	Yoshi-864
31	0.304	NSC:S135758 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazinedione
32	0.303	NSC:S139490 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	emofolin sodium
33	0.303	NSC:S314055 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	SR2555 (nitroimidazole)
34	0.301	NSC:S218321 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	2'-deoxycoformycin
35	0.3	NSC:S6396 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	thio-tepa
36	0.295	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	thioguanine
37	0.293	NSC:S329680 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	hepsulfam
38	0.292	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	m-AMSA (amsacrine)
39	0.29	NSC:S95441 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	methyl-CCNU
40	0.29	NSC:S338947 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	clomesone
41	0.288	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	chlorambucil
42	0.288	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	m-AMSA (amsacrine)
43	0.287	NSC:S9706 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	triethylenemelamine
44	0.284	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	dianhydrogalatitol
45	0.282	NSC:S361456 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	pyrazine diazohydroxide
46	0.28	NSC:S119875 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	cisplatin
47	0.279	NSC:S126771 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	dichloroallyl lawsone
48	0.278	NSC:S286193 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	tiazofurin
49	0.278	NSC:S34462 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	uracil nitrogen mustard
50	0.278	NSC:S95441 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	methyl-CCNU
1	-0.221	NSC:S357704 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	cyanomorpholino-ADR
2	-0.215	NSC:S118742 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	pentamethylmelamine

Table S9. COMPARE Results for **3e** using GI₅₀ as seed in the Standard Agents Database

Rank	P	Target Vector Identity for Display	Target Vector
1	0.727	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	DTIC
2	0.711	NSC:S45388 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	DTIC
3	0.603	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	m-AMSA (amsacrine)
4	0.6	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	chlorambucil
5	0.593	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	melphalan
6	0.586	NSC:S71851 Endpt:GI50 Expld:AVGDATA hiConc:-2.3	A-TGDR
7	0.573	NSC:S752 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	thioguanine
8	0.551	NSC:S344007 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	piperazine alkylator
9	0.539	NSC:S102627 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	Yoshi-864
10	0.532	NSC:S73754 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	fluorodopan
11	0.532	NSC:S293015 Endpt:GI50 Expld:AVGDATA hiConc:-3.2	flavoneacetic acid ester
12	0.528	NSC:S34462 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	uracil nitrogen mustard
13	0.526	NSC:S3088 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	chlorambucil
14	0.522	NSC:S253272 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	caracemide
15	0.515	NSC:S269148 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	menogaril
16	0.515	NSC:S755 Endpt:GI50 Expld:AVGDATA hiConc:-3.1	6-mercaptopurine
17	0.508	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	m-AMSA (amsacrine)
18	0.506	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.8	dianhydrogalatitol
19	0.505	NSC:S6396 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	thio-tepa
20	0.505	NSC:S375575 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	cyclopentenylcytosine
21	0.502	NSC:S9706 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	triethylenemelamine
22	0.501	NSC:S73754 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	fluorodopan
23	0.501	NSC:S141537 Endpt:GI50 Expld:AVGDATA hiConc:-7.0	anguidine
24	0.5	NSC:S329680 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	hepsulfam
25	0.498	NSC:S1895 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	guanazole
26	0.492	NSC:S51143 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	IMPY
27	0.491	NSC:S77037 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	D-tetrandrine
28	0.486	NSC:S71261 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	B-TGDR
29	0.483	NSC:S32065 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	hydroxyurea
30	0.481	NSC:S132313 Endpt:GI50 Expld:AVGDATA hiConc:-3.0	dianhydrogalatitol
31	0.478	NSC:S95441 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	methyl-CCNU
32	0.476	NSC:S8806 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	melphalan
33	0.475	NSC:S284751 Endpt:GI50 Expld:AVGDATA hiConc:-3.5	8Cl-cyc-AMP
34	0.47	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	m-AMSA (amsacrine)
35	0.466	NSC:S303812 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	aphidicolin glycinate
36	0.466	NSC:S296934 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	teroxirone
37	0.464	NSC:S25154 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	pipobroman
38	0.464	NSC:S353451 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	mitozolamide
39	0.461	NSC:S303861 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	L-cysteine analogue
40	0.457	NSC:S122819 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	VM-26 (teniposide)
41	0.457	NSC:S269148 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	menogaril
42	0.449	NSC:S361456 Endpt:GI50 Expld:AVGDATA hiConc:-2.9	pyrazine diazohydroxide
43	0.449	NSC:S762 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	nitrogen mustard
44	0.449	NSC:S406021 Endpt:GI50 Expld:AVGDATA hiConc:-2.6	ARA-6-MP
45	0.447	NSC:S409962 Endpt:GI50 Expld:AVGDATA hiConc:-3.3	BCNU
46	0.444	NSC:S348948 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	cyclodisone
47	0.441	NSC:S82151 Endpt:GI50 Expld:AVGDATA hiConc:-5.0	daunorubicin (daunomycin)
48	0.439	NSC:S192965 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	spirogermanium
49	0.439	NSC:S249992 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	m-AMSA (amsacrine)
50	0.437	NSC:S750 Endpt:GI50 Expld:AVGDATA hiConc:-3.6	busulfan
1	-0.272	NSC:S283162 Endpt:GI50 Expld:AVGDATA hiConc:-4.0	trimethyltrimethylolmelamine
2	-0.251	NSC:S118742 Endpt:GI50 Expld:AVGDATA hiConc:-2.0	pentamethylmelamine
3	-0.217	NSC:S357704 Endpt:GI50 Expld:AVGDATA hiConc:-4.6	cyanomorpholino-ADR

Next three pages.

Figures S7–9. Plots of $\log\text{GI}_{50}$ vs. MGMT, MLH1 and MSH6 protein levels in the NCI60 cell lines for Agents **2d**, **3c–e**.

HPLC Analysis of New Imidazotetrazines

This method was based on the analysis of TMZ (Kim, H.; Likhari, P.; Parker, D.; Statkevich, P.; Marco, A.; Lin, C.-C.; Nomeir, A.A. *J. Pharm Biomed. Anal.*, **2001**, 24, 461–468). A waters e2695 instrument fitted with a Waters symmetry C18 column (5 μ M, 6.6 $\times$ 250 mm) using a mobile phase of 0.1% AcOH(aq) and CH₃CN (75:25) was employed with a flow rate of 1 mL min⁻¹. The effluent was monitored at 316 nm (λ_{max} of TMZ) and peaks were analysed with Empower 3 software. Test compounds were dissolved in DMSO (approx. 5.15 mM in imidazotetrazine) and a 10 μ L aliquot was diluted with 1 mL of mobile phase before loading onto the column. TMZ was used as internal standard and showed a retention time of 3.37 ($\pm$ 0.07) min. DMSO and mobile phase gave small peaks around 2 and 3 min.

Elemental Analysis of Tested Compounds.

	Formula	Found	Required
2a	C ₁₄ H ₁₅ N ₇ O ₂	C, 53.61; H, 4.84; N, 31.63%	C, 53.67; H, 4.83; N, 31.29%
2b	C ₁₅ H ₁₇ N ₇ O ₂ ·0.25H ₂ O·0.25AcOH	C, 53.50; H, 5.15; N, 28.29%	C, 53.67; H, 5.38; N, 28.27%
2c	C ₁₄ H ₁₄ FN ₇ O ₂ ·0.75H ₂ O	C, 48.64; H, 4.22; N, 28.16%	C, 48.77; H, 4.53; N, 28.43%
2d	C ₁₄ H ₁₄ CIN ₇ O ₂ ·0.5H ₂ O	C, 47.16; H, 3.98; N, 26.94%	C, 47.13; H, 4.24; N, 27.48%
2e	C ₁₄ H ₁₄ N ₈ O ₄ ·0.6AcOH·0.2CHCl ₃	C, 44.90; H, 3.70; N, 27.08%	C, 44.76; H, 4.03; N, 27.38%
2f	C ₁₈ H ₂₀ CIN ₇ O ₄ · ¹ / ₃ H ₂ O	C, 49.48; H, 4.70; N, 22.05%	C, 49.22; H, 4.73; N, 22.32%
2g	C ₂₀ H ₁₉ N ₁₃ O ₄ ·0.25H ₂ O	C, 46.87; H, 3.67; N, 35.95%	C, 47.11; H, 3.85; N, 35.71%
2h	C ₁₅ H ₁₆ N ₈ O ₄ ·0.15 H ₂ O	C, 47.95; H, 4.20; N, 30.14%	C, 48.39; H, 4.33; N, 30.09 %
2i	C ₁₅ H ₁₆ N ₈ O ₅ ·0.1 H ₂ O	C, 46.48; H, 4.19; N, 28.47%	C, 46.18; H, 4.19; N, 28.72 %
3a	C ₂₀ H ₁₉ N ₁₃ O ₄ ·H ₂ O·0.8AcOH	C, 44.89; H, 3.77; N, 31.41%	C, 45.39; H, 4.27; N, 31.86%
3b	C ₂₁ H ₂₁ N ₁₃ O ₄ ·0.5H ₂ O·2AcOH	C, 46.48; H, 4.46; N, 28.14%	C, 46.30; H, 4.66; N, 28.07%
3c	C ₂₀ H ₁₈ FN ₁₃ O ₄ ·0.35 H ₂ O·0.3AcOH	C, 45.40; H, 3.63; N, 33.44	C, 45.89; H, 3.47; N, 34.79 %
3d	C ₂₀ H ₁₈ CIN ₁₃ O ₄ ·0.85AcOH	C, 44.26; H, 3.69; N, 30.77%	C, 44.11; H, 3.65; N, 30.81%
3e	C ₂₁ H ₂₁ N ₁₃ O ₅	C, 47.16; H, 3.60; N, 33.44%	C, 47.10; H, 3.95; N, 34.00%
3f	C ₂₁ H ₂₀ N ₁₄ O ₇ ·1.4H ₂ O·0.4AcOH	C, 41.60; H, 3.97; N, 31.20%	C, 43.45; H, 3.47; N, 33.78%

Following pages

¹H NMR Spectra (600 MHz, d₆-DMSO) of compounds **2a-i**, **3a-f**